WO2013132470A2 - New c-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of genista tenera ethyl acetate extracts containing some of those agents - Google Patents
New c-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of genista tenera ethyl acetate extracts containing some of those agents Download PDFInfo
- Publication number
- WO2013132470A2 WO2013132470A2 PCT/IB2013/051916 IB2013051916W WO2013132470A2 WO 2013132470 A2 WO2013132470 A2 WO 2013132470A2 IB 2013051916 W IB2013051916 W IB 2013051916W WO 2013132470 A2 WO2013132470 A2 WO 2013132470A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- tenera
- ethyl acetate
- glucosylgenistein
- genista
- Prior art date
Links
- 241000736969 Genista tenera Species 0.000 title claims abstract description 55
- 239000002024 ethyl acetate extract Substances 0.000 title claims abstract description 44
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title claims abstract description 16
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title claims abstract description 16
- 239000003472 antidiabetic agent Substances 0.000 title claims description 15
- 230000003993 interaction Effects 0.000 title claims description 15
- 230000001225 therapeutic effect Effects 0.000 title claims description 6
- 239000003795 chemical substances by application Substances 0.000 title abstract description 5
- 229940125708 antidiabetic agent Drugs 0.000 title description 4
- 230000000081 effect on glucose Effects 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 78
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 72
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 45
- 239000008103 glucose Substances 0.000 claims abstract description 45
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000419 plant extract Substances 0.000 claims abstract description 17
- 230000003178 anti-diabetic effect Effects 0.000 claims abstract description 16
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 13
- 230000003914 insulin secretion Effects 0.000 claims abstract description 11
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 9
- 239000008280 blood Substances 0.000 claims abstract description 8
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- 239000002021 butanolic extract Substances 0.000 claims abstract description 8
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 6
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 6
- 241000124008 Mammalia Species 0.000 claims abstract description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 49
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 32
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 31
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 29
- 241001465754 Metazoa Species 0.000 claims description 27
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 27
- 229960001052 streptozocin Drugs 0.000 claims description 27
- 229940045109 genistein Drugs 0.000 claims description 23
- 235000006539 genistein Nutrition 0.000 claims description 23
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 23
- 239000003446 ligand Substances 0.000 claims description 20
- 229930003935 flavonoid Natural products 0.000 claims description 19
- 235000017173 flavonoids Nutrition 0.000 claims description 19
- 208000024827 Alzheimer disease Diseases 0.000 claims description 18
- 150000002215 flavonoids Chemical class 0.000 claims description 17
- 102000004877 Insulin Human genes 0.000 claims description 16
- 108090001061 Insulin Proteins 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 16
- 229940125396 insulin Drugs 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 241000196324 Embryophyta Species 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 241000700159 Rattus Species 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000010171 animal model Methods 0.000 claims description 9
- 239000000469 ethanolic extract Substances 0.000 claims description 9
- 230000001896 anti-amyloidogenic effect Effects 0.000 claims description 7
- -1 ethyl acetate flavonoid Chemical class 0.000 claims description 7
- 238000007410 oral glucose tolerance test Methods 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 6
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 6
- 229960005091 chloramphenicol Drugs 0.000 claims description 6
- 238000003570 cell viability assay Methods 0.000 claims description 5
- 241000246169 Genista Species 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 4
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 4
- 230000037353 metabolic pathway Effects 0.000 claims description 4
- 210000000107 myocyte Anatomy 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 210000002027 skeletal muscle Anatomy 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 239000005417 food ingredient Substances 0.000 claims description 2
- 231100001231 less toxic Toxicity 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 231100000167 toxic agent Toxicity 0.000 claims description 2
- 239000003440 toxic substance Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 39
- 230000015572 biosynthetic process Effects 0.000 abstract description 21
- 238000003786 synthesis reaction Methods 0.000 abstract description 16
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 abstract description 6
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000002058 anti-hyperglycaemic effect Effects 0.000 abstract description 4
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 3
- 238000010606 normalization Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000000291 postprandial effect Effects 0.000 abstract description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 235000019439 ethyl acetate Nutrition 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000007912 intraperitoneal administration Methods 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 238000001228 spectrum Methods 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 13
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 238000004741 STD-NMR spectroscopy Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 238000000324 molecular mechanic Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000001049 Amyloid Human genes 0.000 description 6
- 108010094108 Amyloid Proteins 0.000 description 6
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 241000700157 Rattus norvegicus Species 0.000 description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 150000003573 thiols Chemical class 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 5
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 231100000403 acute toxicity Toxicity 0.000 description 5
- 230000007059 acute toxicity Effects 0.000 description 5
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 5
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 5
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- XLEYFDVVXLMULC-UHFFFAOYSA-N 2',4',6'-trihydroxyacetophenone Chemical compound CC(=O)C1=C(O)C=C(O)C=C1O XLEYFDVVXLMULC-UHFFFAOYSA-N 0.000 description 4
- HIWJJOYYZFELEZ-TVBXGXBUSA-N Genistein 8-C-glucoside Natural products O=C1C(c2ccc(O)cc2)=COc2c([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O3)c(O)cc(O)c12 HIWJJOYYZFELEZ-TVBXGXBUSA-N 0.000 description 4
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 4
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- HIWJJOYYZFELEZ-FFYOZGDPSA-N genistein 8-C-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HIWJJOYYZFELEZ-FFYOZGDPSA-N 0.000 description 4
- 230000002641 glycemic effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 125000000468 ketone group Chemical group 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 150000003568 thioethers Chemical class 0.000 description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- XCHBHMOBNNBYAX-UHFFFAOYSA-N 2-methoxy-1-methyl-3,5-dinitrobenzene Chemical compound COC1=C(C)C=C([N+]([O-])=O)C=C1[N+]([O-])=O XCHBHMOBNNBYAX-UHFFFAOYSA-N 0.000 description 3
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 3
- 102000004366 Glucosidases Human genes 0.000 description 3
- 108010056771 Glucosidases Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229960002632 acarbose Drugs 0.000 description 3
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 235000005513 chalcones Nutrition 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- ATMYEINZLWEOQU-GASJEMHNSA-N (3r,4s,5s,6r)-2-fluoro-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1OC(F)[C@H](O)[C@@H](O)[C@@H]1O ATMYEINZLWEOQU-GASJEMHNSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IWKFCBADEWBWGL-UHFFFAOYSA-N 1-phenyl-3-(4-phenylmethoxyphenyl)prop-2-en-1-one Chemical compound C=1C=CC=CC=1C(=O)C=CC(C=C1)=CC=C1OCC1=CC=CC=C1 IWKFCBADEWBWGL-UHFFFAOYSA-N 0.000 description 2
- 238000004466 2D NOESY spectrum Methods 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- ZVTWZSXLLMNMQC-UHFFFAOYSA-N 4-phenylmethoxybenzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCC1=CC=CC=C1 ZVTWZSXLLMNMQC-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100036264 Glucose-6-phosphatase catalytic subunit 1 Human genes 0.000 description 2
- 101710099339 Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000012565 NMR experiment Methods 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- HEMHJVSKTPXQMS-DYCDLGHISA-M Sodium hydroxide-d Chemical compound [Na+].[2H][O-] HEMHJVSKTPXQMS-DYCDLGHISA-M 0.000 description 2
- YNDUPGQMECPWKD-UHFFFAOYSA-N [O-][N+](=O)S[N+]([O-])=O Chemical group [O-][N+](=O)S[N+]([O-])=O YNDUPGQMECPWKD-UHFFFAOYSA-N 0.000 description 2
- 231100000131 acute cytotoxicity Toxicity 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 238000005882 aldol condensation reaction Methods 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000005574 benzylation reaction Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001789 chalcones Chemical class 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000006264 debenzylation reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000386 donor Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000010966 qNMR Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KLBIUKJOZFWCLW-UHFFFAOYSA-N thallium(iii) nitrate Chemical compound [Tl+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O KLBIUKJOZFWCLW-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 238000004791 1D NOESY Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- BWRYEYSRTMFXOG-UVPIGPOJSA-N 3-phenyl-8-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=CC(C2=O)=C1OC=C2C1=CC=CC=C1 BWRYEYSRTMFXOG-UVPIGPOJSA-N 0.000 description 1
- SCZVLDHREVKTSH-UHFFFAOYSA-N 4',5,7-trihydroxy-3'-methoxyflavone Chemical compound C1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 SCZVLDHREVKTSH-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010052341 Impaired insulin secretion Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940126902 Phlorizin Drugs 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- VFRROHXSMXFLSN-KCDKBNATSA-N aldehydo-D-galactose 6-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O VFRROHXSMXFLSN-KCDKBNATSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- UOSZQIQUCYTISS-UHFFFAOYSA-N chrysoeriol Natural products C1=C(O)C(C)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 UOSZQIQUCYTISS-UHFFFAOYSA-N 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000002884 conformational search Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000914 diffusion-ordered spectroscopy Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 239000000348 glycosyl donor Substances 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000005445 isotope effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000020044 madeira Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- HOVAGTYPODGVJG-WLDMJGECSA-N methyl D-glucoside Chemical compound COC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-WLDMJGECSA-N 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 description 1
- 235000019139 phlorizin Nutrition 0.000 description 1
- IOUVKUPGCMBWBT-QNDFHXLGSA-N phlorizin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-QNDFHXLGSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- UPUJGSUSGASQJV-UHFFFAOYSA-J tetrasodium;disulfite Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])=O.[O-]S([O-])=O UPUJGSUSGASQJV-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001551 total correlation spectroscopy Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012579 two dimensional diffusion experiment Methods 0.000 description 1
- 238000002096 two-dimensional nuclear Overhauser enhancement spectroscopy Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention comprises new reaction conditions for the synthesis and the application of compounds type A as antidiabetic agents, which interact with beta-amyloid oligomers hence promoting their potential as anti-amyloid aggregation molecula entities.
- R 6 is hydrogen, hydroxymethyl, alkyl, alkyloxy, amine, amide, alkoxycarbonyl, thioether, thiol, halogens, keto group
- Ar is an aromatic and/or heteroaromatic ring with the formula B, or C
- n 0-5 and m is 0-3,
- Y is NR' , S, CH 2 or 0 and R' is an alkyl group or hydrogen
- R is hydrogen, hydroxyl, alkyl, alkanoyl, alkyoxyl, alkoxycarbonyl, amine, amide, nitro, thioether, thiol, halogens ,
- R are the same or different and are hydrogen, hydroxyl, alkyl, alkanoyl, alkyoxyl, alkoxycarbonyl, amine, amide, nitro, thioether, thiol, halogens
- Compounds type I are present in Genista tenera ethyl acetate extract, which decreased significantly glycaemia basal levels, inhibited alpha-glucosidase and glucose 6-phosphatase, as well as the butanol extract and the ethyl ether for the latter, and also interacted with beta-amyloid oligomers.
- Diabetes mellitus is a chronic, debilitating and often fatal endocrine disease characterized by a status of hyperglycaemia and eventual glycosuria, caused by the inability of tissues to carry out normal metabolism of carbohydrates.
- Two forms of DM are usually described: the insulin dependent DM (type 1) and the non-insulin dependent DM (type 2) .
- the first is characterized by a strong deficiency on insulin secretion, associated with auto-immune destruction of pancreatic ⁇ -cells.
- Type 2 DM is caused by a combination of resistance to insulin and impaired insulin secretion, corresponding to more than 90% of cases.
- Plant Kingdom is a source of bioactive principles against many health problems and a variety of plant metabolites like saponins, alkaloids, flavonoids, anthraquinones , terpenes, coumarins, phenolics, polysaccharides, etc, and plant extracts from a large number of plant families are claimed to possess antidiabetic properties.
- apigenin, chrysoeriol and genistein significantly lowered bood glucose levels of STZ induced diabetic Wistar rats.
- synthesis of ⁇ - ⁇ -D- glucosylgenistein had to be developed. Sato and coworkers have reported the synthesis of this compound starting from 3,5-benzyl protected phloroacetophenone which glucosylation with benzyl protected glucosyl fluoride in the presence of catalytic amount of BF 3 .OEt 2 was followed by aldol condensation with benzyl-protected hydroxybenzaldehyde to give a chalcone.
- Type 2 diabetes along with other age-related degenerative diseases including Alzheimer's, Parkinson's and Huntington's diseases is related with the accumulation of amyloid fibrils. This accumulatiom occurs as an outcome of protein mis-folding and consequent intermolecular hydrogen bonding of extended polypeptide strands.
- amyloids from different diseases may share a common pathway for fibril formation, since they share common structural properties mainly determined by their generic polymer properties . Soluble amyloid oligomers showed also evidence to be the primary pathogenic structure, rather than the mature amyloid fibrils .
- Type 2 diabetes is characterized by islet amyloid deposits derived from islet amyloid polypeptide (IAPP), a protein co- expressed and secreted with insulin by ⁇ -cells, and Alzheimer's disease is characterized by the accumulation of ⁇ -amyloid ( ⁇ ) fibrils. Both diseases have genetic components, and both their amyloid fibrils form into amyloid aggregates in an aqueous environment. It has been suggested that there might be a relationship between amyloid deposits in the brain and pancreatic islets. Furthermore, a recent study proved that type 2 diabetes is more prevalent in Alzheimer's disease patients, versus non Alzheimer's disease control patients. Presently there is no report on C-glycosylflavonoids which interact with amyloid oligomers.
- the invention is concerned with a) Flavonoid extract of Genista tenera characterized by the fact that the extract is obtained from the aerial parts of the plant and the extraction is performed with ethyl acetate .
- Flavonoid extract of b) wherein the extract is used for treating diabetes.
- Plant extract of c) wherein the extract is administered in an amount of 60 milligrams or less per kilogram body weight per day, for seven days, to a mammal model.
- An antidiabetic composition comprising plant extracts from the genus Genista.
- An antidiabetic composition comprising an ethanol extract of plants from the genus Genista.
- An antidiabetic composition comprising an ethanolic extract of Genista tenera.
- An antidiabetic composition comprising the ethyl acetate flavonoid extract from the ethanol extract of Genista tenera .
- Pharmaceutical composition comprising the plant extracts of a) to i) , without hypoglycaemic effects in normoglycaemic animals .
- Pharmaceutical composition comprising the plant extract of a) to i) that normalizes blood glucose levels on the oral glucose tolerance test (OGTT) .
- OGTT oral glucose tolerance test
- a pharmaceutical preparation in dosage unit form adapted for administration to obtain a therapeutic effect comprising, per dosage unit, a therapeutically effective amount of the plant extract of a) to i) .
- a method for treatment of diabetes comprising the step of administering a quantity of flavonoid extract from Genista tenera, to result in a reduction of hyperglycaemia .
- Pharmaceutical composition comprising ethyl acetate and n-butanol extracts from Genista tenera that inhibit the enzyme a-glucos idase , normalizing glucose levels.
- Ethyl acetate extract from G. tenera of a) acts as antiamyloidogenic for Alzheimer's disease.
- Ethyl acetate extract from G. tenera of a) acts a new ligand of ⁇ amyloid (A ⁇ ) oligomers.
- Ethyl acetate extract from G. tenera of a) acts as a new ligand of ⁇ 1-42 oligomers.
- ⁇ - ⁇ -D-Glucosylgenistein t) to x) by itself or by any product of its metabolization, is able to increase insulin sensitivity, by direct or indirect interaction with peripheral cells, which are mainly, but not exclusively, skeletal muscle myocytes.
- peripheral cells which are mainly, but not exclusively, skeletal muscle myocytes.
- aa) ⁇ - ⁇ -D-Glucosylgenistein of t) to x) as a low toxic agent in eukaryotic cells, ten times less toxic than chloramphenicol, when evaluated by the MTT cell viability assay.
- bb) 8- -D-Glucosylgenistein of t) acts as antiamyloidogenic for Alzheimer's disease.
- FIG. 1 Glycaemic curves showing basal fasting and post-load (2 mg glucose/kg) values for intragastric glucose tolerance test .
- FIG. 2 Area under the curve (AUC) for the glycemic curves for all groups.
- FIG. 3 Dynamic curves for insulin secretion, assessed by c- peptide quantification, during basal fasting and post-load intragastric tolerance test (2 mg glucose/kg) .
- FIG. 4 Dynamic curves for circulating insulin during basal fasting and post-load intragastric tolerance test (2 mg glucose/kg) .
- FIG. 5 Antihyperglycemic effect of the extract on diabetic animals (**P ⁇ 0,01 vs STZ; #P ⁇ 0,05; ###P ⁇ 0,001 vs Normal control) .
- FIG. 6 Effect of the extract on Oral Glucose Tolerance Test (**P ⁇ 0,01 vs STZ; #P ⁇ 0,05; ###P ⁇ 0,001 vs Normal control).
- FIG. 7 Effect of the extract on normoglycemic animals.
- FIG. 8 a) 1H NMR spectrum of the 1.5 mg ethyl acetate extract of G. tenera; b) blank STD-NMR spectrum at 2s saturation time of the same sample; c) 1H NMR spectrum of the mixture containing ⁇ 1-42 (80 uM) and 1.5 mg of the ethyl acetate extract of G. tenera; d) STD-NMR spectrum of this mixture at 2s saturation time; e) 1H NMR spectrum of 2 mM Genistein-8-C-glucos ide . All the samples were dissolved in deuterated PBS, pH 7.5, 25°C. The spectrometer frequency was 400 MHz.
- FIG. 9 a) 400 MHz 2D-NOESY spectra of 1.5 mg of the ethyl acetate extract of G. tenera, with a mixing time of 0.8 s. b) trNOESY of the mixture containing ⁇ 1-42 (80 uM) and 1.5 mg of the extract of G. tenera, with a mixing time 0.3 s. Both samples were dissolved in deuterated PBS, at pH 7.5 and 25°C. The cross peaks in the free state.
- FIG. 9 a) 400 MHz 2D-NOESY spectra of 1.5 mg of the ethyl acetate extract of G. tenera, with a mixing time of 0.8 s. b) trNOESY of the mixture containing ⁇ 1-42 (80 uM) and 1.5 mg of the extract of G. tenera, with a mixing time 0.3 s. Both samples were dissolved in deuterated PBS, at pH 7.5 and 25°C. The cross peaks in the free
- FIG. 11 a) 400 MHz 2D-NOESY spectra of 2 mM ⁇ - ⁇ -D- glucopiranosylgenistein with a mixing time of 0.8 s. b) trNOESY of the mixture containing ⁇ 1-42 (80 uM) and 2 mM 8- ⁇ -D-glucopiranosylgenistein, with a mixing time of 0.3 s. Both samples were dissolved in deuterated PBS, at pH 7.5 and 37°C. Positive cross-peak is in red, negative in blue.
- FIG. 12 a) 400 MHz 1H NMR spectrum of 1 mM genistein-7-O- glucoside; b) Blank STD-NMR spectrum of the same sample acquired with a saturation time of 2s; c) 1H NMR spectrum of the mixture containing 80 uM ⁇ 1-42 and 1 mM Genistein-7-O- glucoside; d) STD-NMR spectrum of the same mixture acquired with a saturation time of 2s. Both samples were dissolved in deuterated PBS + 5%DMSO, pH 7.5, 50°C.
- FIG. 13 a) 1H NMR spectrum of 1 mM genistein; b) STD-NMR spectrum of the same sample acquired with a saturation time of 2s; c) 1H NMR spectrum of the mixture containing 80 uM ⁇ 1-42 and 1 mM Genistein; d-h STD-NMR spectra of the same mixture acquired with different saturation times. (B, 0.5 s; C, 1,2 s; D, 2,0 s; E 3,0 s; F, 5,0 s) . All samples were dissolved in deuterated PBS, at pH 7.5 and 37°C and recorded at 400 MHz.
- FIG. 14 The two conformations around the glycosidic linkage ⁇ - ⁇ -D-glucopiranosylgenistein .
- the global minimum is shown in violet, while the local minimum is in yellow. NOE experimental contacts are highlighted.
- FIG. 15 Superimposition of the possible conformers of genistein-7-O-glucoside according to MM3* calculations. They are basically isoenergetic .
- the in vitro acute toxicity of the synthesized compound in eukaryotic cells was assessed using the MTT cell viability assay.
- the IC 50 value was ca.lO times higher than that of the commercial drug chloramphenicol, demonstrating the low toxicity of this antidiabetic agent.
- Compound 8-p-D-glucopyranosylgenistein is the major component of the flavonoids ethyl acetate extract of Genista tenera, a plant used in tradicional medicine to treat diabetic patients The entire extract also showed antidiabetic activity. Given daily to STZ Wistar rats (60 mg/Kg/day, i. p.), for 7 days, it induced a significant decrease (52%, P ⁇ 0.05) of glycaemia basal levels. The protecting effect of the extract was confirmed by the glucose tolerance curve, where a significant decrease of glycaemia was observed 120 min after oral administration (10 mL/Kg) of a 20% glucose aqueous solution.
- Soluble amyloid oligomers show also evidence to be the primary pathogenic structure, rather than the mature amyloid fibrils.
- Type 2 diabetes is characterized by islet amyloid deposits derived from islet amyloid polypeptide (IAPP), a protein co-expressed and secreted with insulin by ⁇ -cells, and_Alzheimer' s disease is characterized by the accumulation of ⁇ -amyloid ( ⁇ ) fibrils. Both diseases have genetic components, and both their amyloid fibrils form into amyloid aggregates in an aqueous environment. The presence of compounds able to bind ⁇ 1-42 oligomers in ethyl acetate extract of G.
- IAPP islet amyloid polypeptide
- ⁇ ⁇ -amyloid
- this plant is a source of bioactive compounds with a potential anti-amyloid aggregation effect, useful in the therapeutics of diabetes and/or Alzheimer's disease (AD) and ⁇ 1-42 oligomers seem to act as an in vitro model of type 2 diabetes for this type of compounds, supporting the results obtained for the extract and for 8-p-D-glucosylgenistein in the biological assays with STZ-induced diabetic rats.
- AD Alzheimer's disease
- 1,4-dioxane aq. NaOH 50% (w/v) , 18 h, reflux, 2.
- Ac 2 0, Py, DMAP, 1 h, r.t., 60 %; g) 1.
- TTN (2.0 eq.) was added to a solution of 8 (1.67 mmol) in (MeO) 3 CH (45 mL) and MeOH (45 mL) .
- the reaction mixture stirred for 24 h at 40 °C and then sodium bissulfite was added to promote the reduction of Tl (III) to Tl (I) .
- Solid was removed by filtration, water was added and the mixture was extracted with DCM. The combined extracts were dried over MgS0 4 , filtered off and concentrated.
- Tests were conducted using male Wistar rats, with weight around 250 g. Animals were maintained under stable conditions of temperature (25°C), light-dark periods (12h) , and feeding (maintenance rat chow) . Both food and water were available ad lib. Food was removed 24h before testing, to ensure that the animals were on the fasting state. Access to water was maintained during this period.
- a state of hyperglycaemia adequate to the diagnosis of diabetes was induced experimentally through chemical intervention.
- STZ streptozotocin
- Hyperglicaemia was checked two days after STZ administration by quantifying glucose on a blood sample collected by tail puncture. The animals on the control group received instead an injection of the same volume of saline, with normoglycaemia checked also after two days.
- Group I Control was given one saline injection, and two days after started a 7-days treatment with saline + 5% ethanol. This group represents normoglycaemic control.
- Group II STZ was first treated with streptozotocin (40 mg/kg, i.p.) and then for 7 days with saline + 5% ethanol. This group represents the diabetic condition.
- Group III STZ+ 8G was first given STZ (40 mg/kg, i.p.) and then a 7-days treatment with synthesized 8-C-glucosilisoflavone (4 mg/kg/day in saline + 5% ethanol, i .p . ) .
- Animals were anesthetised with sodium pentobarbital (65 mg/kg) after a 24h fasting period. Immediately after, they were placed on a homoeothermic apparatus. Body temperature was maintained at 37 °C to avoid metabolic changes induced by hypoglycaemia . An exterior loop was surgically placed between the femoral vein and artery, and a catheter was placed on the stomach. After surgery completion, recovery before testing was allowed for a minimum period of 30 minutes. Anaesthesia was maintained throughout the experiment with a constant sodium pentobarbital perfusion on the femoral vein.
- Glucose tolerance testing was done first by monitoring blood glycaemia at the fasting state for 20 minutes, after which 2 ml of a glucose solution (2 mg glucose/kg) was administered through the gastric catheter, directly into the stomach. Blood glycaemia was thus measured at regular intervals, by a bench glucose analyzer, both on baseline fasting (from -20 to 0 minutes) and on the post-load period (from 0 to 180 minutes) .
- Blood samples were also collected for insulin and c-peptide quantification, both at baseline and post-load time points (- 20, -10, 0, 5, 15, 30, 45, 60, 90, 120, 180 minutes) . These samples were quickly centrifuged and serum was stored at - 80°C for RIA analysis.
- Mean relates to n observations, in which n represents the number of animals tested (between 5 and 8, depending on the group) .
- Mean values between groups were compared using one-way analysis of variance (ANOVA) , followed by a Tukey post-test. Differences were considered statistically significant when p ⁇ 0.05.
- Post-load endpoint glycaemia considered here at 180 minutes after gastric glucose loading, was likewise raised (from 112.0 ⁇ 4.3 on control to 245.4 ⁇ 42.8 mg/dl on STZ; p ⁇ 0.01) .
- Total glucose excursion was thus elevated (from an area under the glycaemic curve (AUC) of 23659 ⁇ 990 on controls to 49539 ⁇ 7309 on STZ; p ⁇ 0.01).
- glycaemic parameters were all returned to normal control values on those diabetic rats subjected to the 7-days i.p. administration of 8-C-glucosilisoflavone (4 mg/kg, daily) .
- STZ administration lead to a decrease on glucose-induced insulin secretion, as estimated through c-peptide insulin parameters, as expected quantification (from an AUC of 287124 ⁇ 37907 on controls to 172261 ⁇ 18480 on STZ; p ⁇ 0.05) and likewise a decrease on circulating insulin (from an AUC of
- Acute cytotoxicity measurements were performed by the MTT method.
- the 3- ( 4 , 5-dimethylthiazol-2-yl ) -2 , 5- diphenyltetrazolium bromide (MTT) assay was used to quantify metabolically viable cells in all samples.
- Adherent cells mouse HII4E hepatoma cells
- Positive control hydrogen peroxide
- DMSO negative control
- chloramphenicol were also included.
- MTT was added to the cells at a final concentration of 0.5 mg/mL, followed by an incubation period of 3 h to allow the formazan crystals to form.
- Genista tenera were collected in the Island of Madeira, dried in the absence of direct sunlight, and pulverized to form a plant powder.
- Plant powder was extracted with ethanol 96% (Panreac, VWR) , in a Soxhlet extractor.
- the ethanol extract was concentrated to dryness at low temperature (40 °C) under reduced pressure, in a rotary evaporator Buchi R-200.
- the ethanol extract was suspended in hot water (80 °C) and flavonoids extracted sequentially with diethyl ether, ethyl acetate and n-butanol.
- the tree different extracts were concentrated to dryness in a rotary evaporator Buchi R-200.
- This invention concerns to the ethyl acetate extract of flavonoids . Antihyperglycaemic activity
- the antihyperglycemic activity of the Genista tenera flavonoid extract was evaluated in a mammal model.
- the extract was dissolved in saline + 5% de ethanol (v/v) and administered (60 mg/Kg/day.), for 7 days
- mice were injected intraperitoneally (i.p.) with a single dose (40 mg/Kg) of streptozotocin (STZ) dissolved in saline. Extract effect in diabetic animals
- Group III Diabetic+ Extract (60 mg/Kg/day, i.p.)
- Extract was given daily, for seven days .
- control group was injected (i.p.) with the solvent of the extract (saline + 5% ethanol)
- a second group was treated with the extract (60 mg/Kg, i.p.), 5 min before the OGTT.
- the extract displays encouraging efficacy in normalizing glucose levels of STZ diabetic rats.
- the mechanism of the antidiabetic activity of the extracts was evaluated in terms of their inhibitory activity on the enzymes a-glucosidase and glucose-6-phosphatase, which are involved in the metabolism of glucose.
- the ethyl acetate, n- butanol and diethyl ether were tested, according to the following procedures:
- Enzyme solutions were prepared using rat intestinal acetone powder (Sigma, St. Louis, Mo., USA) as the source of a- glucosidase.
- 50 mg of rat intestinal acetone powder were homogenized with 10 mL of 0,1 M maleate buffer at pH 6.9 and centrifuged at 6000 xg for 20 min at 4°C. The supernatant obtained before the experiment was used as the enzyme solution for the alpha-glucosidase reaction.
- the experimental procedure was carried out by the methology of Mai and coworkers, although with slight modifications. 50 L of the enzyme solution was pre-incubated with 50 L of the plant extract solution and 100 L of 0,1 M maleate buffer (PH 6,9) at 37 °C for 10 min.
- the enzyme reaction was then started by adding 50 L of maltose substrate solution (1% w/v in maleate buffer (pH 6.9)) .
- the enzymatic reaction was allowed to proceed at 37 °C for 30 min and then stopped by heating at 100°C for 5 min.
- the generated glucose was quantified with a commercial assay kit ( Sigma-Aldrich) at 540 nm.
- the enzyme solution was replaced with 0,1 M maleate buffer and the same procedure was carried out as above.
- Acarbose was tested as reference compound, in a concentration of 400 mg/L. Each extract sample or controls were measured five times. The rate of a- glucosidase inhibition was calculated as a percentage of the control by the formula below:
- ethyl acetate and n-butanol extracts revealed a significant a-glucosidase inhibition (enzymatic activity reduced to 2,36 % and 0,97%, respectively) being these two extracts much more effective than the standard drug acarbose, which reduced the enzymatic activity to 17,39 %.
- Enzymatic solution was prepared with rabbit liver microsomes as a source of glucose- 6-fosfatase as described previously.
- the microsomal protein (16.74 mg) was resuspended in 0.837 mL HEPES (5 mM ,pH 6.5) containing 0.25 mM sucrose, and 1 mM MgC12, and frozen at-80 °C until use.
- Enzymatic assays were performed by the method described by Burchell et al. with some modifications.
- G-6-Pase assay was carried out in a final volume of 100 i with 5 mM glucose- 6-phosphate (G-6-P) , 2 mM EDTA, 16 mM HEPES pH 6.5 (solution A) and the enzyme.
- reaction was carried out at 37 °C for 60 min without shaking, and stopped by the addition of 1 mL of sulphuric acid (0.33 M) , 0.28% ammonium molybdate, 1.11% SDS and 1.11% ascorbic acid (solution B) .
- the reaction was incubated at 47 °C for 20 min and the absorption recorded in a Shimadzu UV-1700, at 820 nm. In order to study the effect of each extract, it was added to the G-6-Pase assay at a final concentration of 400 mg/mL.
- a batch of ⁇ 1-42 was selected that contained pre- amyloidogenic seeds highly toxic to N2a cells. The selection was made through sample characterization by NMR spectroscopy, as previously described Immediately before use, lyophilized ⁇ 1-42 was dissolved in 10 mM NaOD in D 2 0 at a concentration of 160 ⁇ , then diluted 1:1 with 10 mM phosphate buffer saline, pH 7.4 containing 100 mM NaCl (PBS) and ethyl acetate extract of G. tenera or one of the tested compounds.
- PBS mM phosphate buffer saline
- the final concentrations/quantities of ⁇ 1-42, genistein-8-C- glucoside, genistein-7-O-glucoside, genistein and the ethyl acetate extract of G. tenera in the samples were 80 uM, 2 mM, 1 mM, 1 mM and 3 mg respectively.
- the pH of each sample was verified with a Microelectrode (Mettler Toledo) for 5 mm NMR tubes and adjusted with NaOD and/or DC1. All pH values were corrected for isotope effect.
- NMR experiments were recorded on a Varian 400-MHz Mercury instrument.
- the basic VARIAN sequences were employed for 2D- TOCSY, 2D-NOESY, 13 C-HSQC, DOSY and STD experiments.
- STD a train of Gaussian-shaped pulses each of 50 ms was employed to saturate selectively the protein envelope; the total saturation time of the protein envelope was adjusted by the number of shaped pulses and was varied between 3 s and 0.3 s.
- a 1 H spectrum was acquired with a recycle delay of 60 s to achieve the complete relaxation of all the resonances at each scan.
- the quantification was performed by comparing the DSS methyl resonance integral with the ⁇ - ⁇ -D- glucopiranosylgenistein aromatic resonance integrals.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention concerns the antidiabetic activity of compounds type A, namely of 8-β-D-glucosylgenistein, which is not toxic to eukaryotic cells and has demonstrated to produce complete normalization of fasting hyperglycaemia, to reduce excessive postprandial glucose excursion, to increase glucose-induced insulin secretion and insulin sensitivity. An alternative synthesis for this molecular entity and its binding ability to β-amyloid oligomers is also included in the present invention, which also comprises Genista tenera ethyl acetate extract for use as antihyperglycaemic agent i.e. for lowering blood glucose levels in mammals that are pre- diabetic or have type 2 or type 1 diabetes. The inhibitory activity of α-glucosidase by Genista tenera ethyl acetate and butanol extracts and that of glucose-6- phosphatase by these two extracts and the diethyl ether plant extract is also part of the present invention.
Description
DESCRIPTION
NEW C-GLYCOSYLPOLYPHENOL ANTIDIABETIC AGENTS, EFFECT ON GLUCOSE TOLERANCE AND INTERACTION WITH BETA-AMYLOID .
THERAPEUTIC APPLICATIONS OF THE SYNTHESIZED AGENT (S) AND OF GENISTA TENERA ETHYL ACETATE EXTRACTS CONTAINING SOME OF
THOSE AGENTS
Technical field of the invention
The present invention comprises new reaction conditions for the synthesis and the application of compounds type A as antidiabetic agents, which interact with beta-amyloid oligomers hence promoting their potential as anti-amyloid aggregation molecula entities.
Wherein Ri, R3, R4 and R5 are the same or different and are hydrogen, alkyl, alkyloxy, amine, amide, alkoxycarbonyl, thioether, thiol, halogens, keto group and R2 is alkyl, alkyloxy, amine, amide, alkoxycarbonyl, thioether, thiol, halogens, keto group or hydrogen, alkyl, alkyloxy, amine, amide, alkoxycarbonyl, thioether, thiol, halogens, keto group and Ri different from R or ¾ = R but different from hydroxyl
with a glucosyl moiety. Wherein R6 is hydrogen, hydroxymethyl, alkyl, alkyloxy, amine, amide, alkoxycarbonyl, thioether, thiol, halogens, keto group
B C
Where n is 0-5 and m is 0-3,
Where X is N or C,
Where Y is NR' , S, CH2 or 0 and R' is an alkyl group or hydrogen
When n=l, R is hydrogen, hydroxyl, alkyl, alkanoyl, alkyoxyl, alkoxycarbonyl, amine, amide, nitro, thioether, thiol, halogens ,
When n≥2, R are the same or different and are hydrogen, hydroxyl, alkyl, alkanoyl, alkyoxyl, alkoxycarbonyl, amine, amide, nitro, thioether, thiol, halogens
They show an extensive therapeutical impact on an animal model of beta-cell failure and diabetes and produce complete normalization of fasting hyperglycaemia in streptozotocin ( STZ ) -induced diabetic Wistar rats. They (or their metabolic products) interfere beneficially on various parameters of glucose and insulin metabolic pathways by increasing glucose- induce insulin secretion, and also insulin sensitivity. The in vitro acute toxicity of the synthesized compounds in eukaryotic cells demonstrated the low toxicity of these antidiabetic molecular entities.
Compounds type I are present in Genista tenera ethyl acetate extract, which decreased significantly glycaemia basal levels, inhibited alpha-glucosidase and glucose 6-phosphatase, as well as the butanol extract and the ethyl ether for the latter, and also interacted with beta-amyloid oligomers.
Background of invention
Diabetes mellitus (DM) is a chronic, debilitating and often fatal endocrine disease characterized by a status of hyperglycaemia and eventual glycosuria, caused by the inability of tissues to carry out normal metabolism of carbohydrates. Two forms of DM are usually described: the insulin dependent DM (type 1) and the non-insulin dependent DM (type 2) . The first is characterized by a strong deficiency on insulin secretion, associated with auto-immune destruction of pancreatic β-cells. Type 2 DM is caused by a combination of resistance to insulin and impaired insulin secretion, corresponding to more than 90% of cases.
As a result of the long term hyperglycaemia, severe damage of body systems can occur, especially on nerves, blood vessels, heart, eyes, and kidneys conducing to neuropathies, retinopathies, nephropathies and cardiovascular complications. Due to population growth, aging, urbanization, lifestyle alterations and increasing prevalence of obesity, the last two decades have seen an explosive worldwide increase in people diagnosed with DM. According to the last projections from the International Diabetes Federation (IDF) and World Health Organization (WHO) this disease will affect 380 million people in 2025.
DM is becoming the third "killer" of mankind, along with cancer, cardiovascular and cerebrovascular diseases. Because of its prevalence, the WHO has declared DM as an epidemic disease. Although patients can, in most cases, control their glycaemia with the available therapeutically means, together with a correct nutrition, the research of new and effective medicines for the prevention and treatment of this chronic disease is absolutely needed.
Plant Kingdom is a source of bioactive principles against many health problems and a variety of plant metabolites like saponins, alkaloids, flavonoids, anthraquinones , terpenes, coumarins, phenolics, polysaccharides, etc, and plant extracts from a large number of plant families are claimed to possess antidiabetic properties.
Previous research work [4,5,6,7] was developed by the Carbohydrate Chemistry Group of CQB-FCUL [RG-CHEM-LVT-Lisboa- 612-640] on the antidiabetic plant Genista tenera concerning extracts preparation and the identification of its major constituents: alkaloids and flavonoids. The n-butanol extract of flavonoids revealed a promising antidiabetic activity on an experimental animal model. In vitro toxicity studies of this extract showed no evidence for acute cytotoxicity or genotoxicity . The ethanol extract components were studied with the exception of 8-p-D-glucosylgenistein, which is not commercially available. The components apigenin, chrysoeriol and genistein significantly lowered bood glucose levels of STZ induced diabetic Wistar rats. Hence, synthesis of δ-β-D- glucosylgenistein had to be developed. Sato and coworkers have reported the synthesis of this compound starting from
3,5-benzyl protected phloroacetophenone which glucosylation with benzyl protected glucosyl fluoride in the presence of catalytic amount of BF3.OEt2 was followed by aldol condensation with benzyl-protected hydroxybenzaldehyde to give a chalcone. Its oxidative rearrangement with thallium (III) nitrate (TTN) and subsequent acid-catalyzed cyclization and debenzylation led to the final product. However, trials to repeat this synthesis were not successful and the reported yields are not reproducible. In addition, the compound has never been reported to be active against diabetes.
Type 2 diabetes, along with other age-related degenerative diseases including Alzheimer's, Parkinson's and Huntington's diseases is related with the accumulation of amyloid fibrils. This accumulatiom occurs as an outcome of protein mis-folding and consequent intermolecular hydrogen bonding of extended polypeptide strands. According to Glabe, amyloids from different diseases may share a common pathway for fibril formation, since they share common structural properties mainly determined by their generic polymer properties . Soluble amyloid oligomers showed also evidence to be the primary pathogenic structure, rather than the mature amyloid fibrils .
Type 2 diabetes is characterized by islet amyloid deposits derived from islet amyloid polypeptide (IAPP), a protein co- expressed and secreted with insulin by β-cells, and Alzheimer's disease is characterized by the accumulation of β-amyloid (Αβ) fibrils. Both diseases have genetic components, and both their amyloid fibrils form into amyloid aggregates in an aqueous environment. It has been suggested that there
might be a relationship between amyloid deposits in the brain and pancreatic islets. Furthermore, a recent study proved that type 2 diabetes is more prevalent in Alzheimer's disease patients, versus non Alzheimer's disease control patients. Presently there is no report on C-glycosylflavonoids which interact with amyloid oligomers.
Summary of the invention
The invention is concerned with a) Flavonoid extract of Genista tenera characterized by the fact that the extract is obtained from the aerial parts of the plant and the extraction is performed with ethyl acetate . b) Flavonoid extract of a) wherein the extract is for use as a medicament and/or a nutraceutic or functional food ingredient .
c) Flavonoid extract of b) , wherein the extract is used for treating diabetes. d) Plant extract of c) , wherein the extract is administered in an amount of 60 milligrams or less per kilogram body weight per day, for seven days, to a mammal model. e) Use of the extract of a) for the preparation of a medicament for the treatment of diabetes type 1 or 2, characterized in that the extract is administered
intraperitoneally in a dose of 60 mg/Kg or less of body weight . f) An antidiabetic composition comprising plant extracts from the genus Genista. g) An antidiabetic composition comprising an ethanol extract of plants from the genus Genista. h) An antidiabetic composition comprising an ethanolic extract of Genista tenera. i) An antidiabetic composition comprising the ethyl acetate flavonoid extract from the ethanol extract of Genista tenera . j) Pharmaceutical composition comprising the plant extracts of a) to i) , without hypoglycaemic effects in normoglycaemic animals . k) Pharmaceutical composition comprising the plant extract of a) to i) that normalizes blood glucose levels on the oral glucose tolerance test (OGTT) .
1) A pharmaceutical preparation in dosage unit form adapted for administration to obtain a therapeutic effect, comprising, per dosage unit, a therapeutically effective amount of the plant extract of a) to i) .
m) Medical use of the plant extract of a) to e) , for treatment of diabetes, wherein a dose of 60 mg/kg or less of body weight is administered. n) A method for treatment of diabetes comprising the step of administering a quantity of flavonoid extract from Genista tenera, to result in a reduction of hyperglycaemia . o) Pharmaceutical composition comprising ethyl acetate and n-butanol extracts from Genista tenera that inhibit the enzyme a-glucos idase , normalizing glucose levels. p) Pharmaceutical composition comprising diethyl ether, ethyl acetate and n-butanol extracts from Genista tenera that inhibits the enzyme glucose-6- phosfatase, normalizing glucose levels. q) Ethyl acetate extract from G. tenera of a) acts as antiamyloidogenic for Alzheimer's disease. r) Ethyl acetate extract from G. tenera of a) acts a new ligand of β amyloid (A β) oligomers. s) Ethyl acetate extract from G. tenera of a) acts as a new ligand of Αβ1-42 oligomers. t) 8- -d-Glucosylgenistein for the control of glycaemia on a diabetic animal models, both on the fasting and post- load periods .
u) 8- -D-Glucosylgenistein of t) for the control of glycaemia on a diabetic animal model, both on the fasting and post-load periods.
v) 8- -D-Glucosylgenistein (4 mg/kg/day or less, 7 days) of t) and u) for the return of basal fasting glycaemia.
w) 8- -D-Glucosylgenistein (4 mg/kg/day or less, 7 days) of t) , u) and v) for the return of post-load glucose excursions to normal control values on rats made diabetic by prior destruction of pancreatic cells with streptozotocin (40 mg/kg) .
x) δ-β-D-Glucosylgenistein of t) , to interfere beneficially, by itself or by any product of its metabolization, on various parameters of glucose and insulin metabolic pathways.
y) 8- -D-Glucosylgenistein of t) to x) , by itself or by any product of its metabolization, to increase glucose- induced insulin secretion, by direct or indirect interaction with pancreatic cells.
z) δ-β-D-Glucosylgenistein t) to x) , by itself or by any product of its metabolization, is able to increase insulin sensitivity, by direct or indirect interaction
with peripheral cells, which are mainly, but not exclusively, skeletal muscle myocytes. aa) δ-β-D-Glucosylgenistein of t) to x) , as a low toxic agent in eukaryotic cells, ten times less toxic than chloramphenicol, when evaluated by the MTT cell viability assay. bb) 8- -D-Glucosylgenistein of t) acts as antiamyloidogenic for Alzheimer's disease. cc) 8- -D-Glucosylgenistein of t) to v) acts a new ligand of β amyloid (A β) oligomers. dd) 8- -D-Glucosylgenistein of t) to cc) that acts as a new ligand of Αβ1-42 oligomers. ee) Pharmaceutical composition comprising 8-β-Ό- glucosylgenistein in combination with several flavonoids identified in the ethyl acetate extract of G. tenera. ff) Genistein 7-0- -D-glucoside, present in ethyl acetate extract of G. tenera of a) acting as antiamyloidogenic for Alzheimer's disease. gg) Genistein 7- -D-0-glucoside present in ethyl acetate extract of G. tenera of a) acting a new ligand of β amyloid (A β) oligomers.
hh) Genistein 7- -D-0-glucoside present in ethyl acetate extract of G. tenera of a) acting as a new ligand of Αβ1-42 oligomers. ii) Genistein present in ethyl acetate extract of G. tenera of a) acting as antiamyloidogenic for Alzheimer's disease . jj) Genistein present in ethyl acetate extract of G. tenera of a) acting as new ligand of β amyloid (A β) oligomers . kk) Genistein present in ethyl acetate extract of G. tenera of a) acting as a new ligand of Αβ1-42 oligomers.
Description of figures
FIG. 1: Glycaemic curves showing basal fasting and post-load (2 mg glucose/kg) values for intragastric glucose tolerance test .
FIG. 2: Area under the curve (AUC) for the glycemic curves for all groups.
FIG. 3: Dynamic curves for insulin secretion, assessed by c- peptide quantification, during basal fasting and post-load intragastric tolerance test (2 mg glucose/kg) .
FIG. 4: Dynamic curves for circulating insulin during basal fasting and post-load intragastric tolerance test (2 mg glucose/kg) .
FIG. 5: Antihyperglycemic effect of the extract on diabetic animals (**P<0,01 vs STZ; #P<0,05; ###P<0,001 vs Normal control) . White column represents "untreated", n=5; black column represents "treated" with STZ, n=4; and grey column represents "treated" with STZ plus extract, n=5.
FIG. 6: Effect of the extract on Oral Glucose Tolerance Test (**P<0,01 vs STZ; #P<0,05; ###P<0,001 vs Normal control). White column represents "untreated", n=5; black column represents "treated" with STZ, n=4; and grey column represents "treated" with STZ plus extract, n=5.
FIG. 7: Effect of the extract on normoglycemic animals.
FIG. 8: a) 1H NMR spectrum of the 1.5 mg ethyl acetate extract of G. tenera; b) blank STD-NMR spectrum at 2s saturation time of the same sample; c) 1H NMR spectrum of the mixture containing Αβ1-42 (80 uM) and 1.5 mg of the ethyl acetate extract of G. tenera; d) STD-NMR spectrum of this mixture at 2s saturation time; e) 1H NMR spectrum of 2 mM Genistein-8-C-glucos ide . All the samples were dissolved in deuterated PBS, pH 7.5, 25°C. The spectrometer frequency was 400 MHz.
FIG. 9: a) 400 MHz 2D-NOESY spectra of 1.5 mg of the ethyl acetate extract of G. tenera, with a mixing time of 0.8 s. b) trNOESY of the mixture containing Αβ1-42 (80 uM) and 1.5 mg of the extract of G. tenera, with a mixing time 0.3 s. Both samples were dissolved in deuterated PBS, at pH 7.5 and 25°C. The cross peaks in the free state.
FIG. 10: a) 1H NMR spectrum of 2 mM δ-β-D- glucopiranosylgenistein; b) Blank STD-NMR spectrum of the same sample acquired with a saturation time of 2s; c) 1H NMR spectrum of the mixture containing 80 uM Αβ1-42 and 2 mM 8-β- D-glucopiranosylgenistein; d-h STD-NMR spectra of the same mixture acquired with different saturation times. (B, 0.5 s; C, 1.2 s; D, 2,0 s; E 3.0 s; F, 5.0 s) . Both samples were dissolved in deuterated PBS, pH 7.5, 25°C. The spectra were recorded at 400 MHz. The key resonances are highlighted in spectrum 4a in the bottom part.
FIG. 11: a) 400 MHz 2D-NOESY spectra of 2 mM δ-β-D- glucopiranosylgenistein with a mixing time of 0.8 s. b) trNOESY of the mixture containing Αβ1-42 (80 uM) and 2 mM 8- β-D-glucopiranosylgenistein, with a mixing time of 0.3 s. Both samples were dissolved in deuterated PBS, at pH 7.5 and 37°C. Positive cross-peak is in red, negative in blue.
FIG. 12: a) 400 MHz 1H NMR spectrum of 1 mM genistein-7-O- glucoside; b) Blank STD-NMR spectrum of the same sample acquired with a saturation time of 2s; c) 1H NMR spectrum of the mixture containing 80 uM Αβ1-42 and 1 mM Genistein-7-O- glucoside; d) STD-NMR spectrum of the same mixture acquired with a saturation time of 2s. Both samples were dissolved in deuterated PBS + 5%DMSO, pH 7.5, 50°C.
FIG. 13: a) 1H NMR spectrum of 1 mM genistein; b) STD-NMR spectrum of the same sample acquired with a saturation time of 2s; c) 1H NMR spectrum of the mixture containing 80 uM Αβ1-42 and 1 mM Genistein; d-h STD-NMR spectra of the same mixture acquired with different saturation times. (B, 0.5 s; C, 1,2 s; D, 2,0 s; E 3,0 s; F, 5,0 s) . All samples were
dissolved in deuterated PBS, at pH 7.5 and 37°C and recorded at 400 MHz.
FIG. 14: The two conformations around the glycosidic linkage δ-β-D-glucopiranosylgenistein . The global minimum is shown in violet, while the local minimum is in yellow. NOE experimental contacts are highlighted.
FIG. 15. Superimposition of the possible conformers of genistein-7-O-glucoside according to MM3* calculations. They are basically isoenergetic .
Detailed description of the invention
Diabetes is a growing public health concern and will probably be one of the main medical conditions that need addressing over the next decade. Development of new and nontoxic drugs and functional foods/nutraceuticals to control both diabetes type 1 and type 2 remains a priority area of research. The compound 8-p-D-glucopyranosylgenistein ( 8-glucosylgenistein, formerly named as genistein 8-C-glucoside) was synthesized via reaction conditions alternative to those reported in the literature. This compound has shown an extensive therapeutical impact on an animal model of beta-cell failure and diabetes. Indeed, a treatment of 7 daily intraperitoneal (i.p.) injections (4mg/kg each administration) to streptozotocin (STZ) -induced diabetic Wistar rats has demonstrated to produce complete normalization of fasting hyperglycaemia, and a radical amelioration of excessive postprandial glucose excursions to values similar to those observed in healthy normal rats, as given by an intragastric
glucose tolerance test. Measurements of circulating insulin and c-peptide were also obtained throughout the glucose tolerance test, to characterize the beneficial effects of the compound on insulin secretion, clearance and action. The synthesized 8-p-D-glucosylgenis tein is able to interfere beneficially, by itself or by any product of its metabolism, on various parameters of glucose and insulin metabolic pathways. It is able to increase glucose-induced insulin secretion, by direct or indirect interaction with pancreatic cells, and also insulin sensitivity, by direct or indirect interaction with peripheral cells, which are mainly, but not exclusively, skeletal muscle myocytes.
The in vitro acute toxicity of the synthesized compound in eukaryotic cells was assessed using the MTT cell viability assay. The IC50 value was ca.lO times higher than that of the commercial drug chloramphenicol, demonstrating the low toxicity of this antidiabetic agent.
Compound 8-p-D-glucopyranosylgenistein is the major component of the flavonoids ethyl acetate extract of Genista tenera, a plant used in tradicional medicine to treat diabetic patients The entire extract also showed antidiabetic activity. Given daily to STZ Wistar rats (60 mg/Kg/day, i. p.), for 7 days, it induced a significant decrease (52%, P< 0.05) of glycaemia basal levels. The protecting effect of the extract was confirmed by the glucose tolerance curve, where a significant decrease of glycaemia was observed 120 min after oral administration (10 mL/Kg) of a 20% glucose aqueous solution. Hypoglycaemic effect of the extract was also evaluated in
normoglycaemic animals and animals treated with the extract. The two groups responded similarly to the glucose kinetics in blood for 180 min, proving that the extract does not inhibit glucose transport. These biological properties show the efficacy of this extract for functional foods and nutraceutical purposes, and that of the synthesized compound for more intense drug intervention . Type 2 diabetes, along with other age-related degenerative diseases including Alzheimer's, Parkinson's and Huntington's diseases, is related with the accumulation of amyloid fibrils. This accumulation occurs as an outcome of protein misfolding and consequent intermolecular hydrogen bonding of extended polypeptide strands. Amyloids from different diseases may share a common pathway for fibril formation, since they have common structural properties. Soluble amyloid oligomers show also evidence to be the primary pathogenic structure, rather than the mature amyloid fibrils. Type 2 diabetes is characterized by islet amyloid deposits derived from islet amyloid polypeptide (IAPP), a protein co-expressed and secreted with insulin by β-cells, and_Alzheimer' s disease is characterized by the accumulation of β-amyloid (Αβ) fibrils. Both diseases have genetic components, and both their amyloid fibrils form into amyloid aggregates in an aqueous environment. The presence of compounds able to bind Αβ1-42 oligomers in ethyl acetate extract of G. tenera was investigated by using Saturation Transfer Difference (STD) and tr-NOESY NMR experiments. These experiments unequivocally demonstrate that the extract, 8-p-D-glucosylgenistein and genistein 7-p-D-0-glucoside , the second major constituent of the extract, bind to Αβ oligomers. However the latter suffers
intermolecular aromatic-aromatic or carbohydrate-aromatic stacking leading to the formation of a supramolecule , and consequently the C-glucosylgenistein presents a higher affinity to Αβ oligomers than its O-glucoside. Moreover, quantitative NMR techniques confirmed the presence of δ-β-D- glucosylgenistein, in a concentration of 92 mg/g of the ethyl acetate extract of G. tenera. Its aglycone is mostly involved in the binding but the glucosyl residue also participates in the interaction process adopting a preferential conformation in which its a-face points towards H2 of the aglycone. Insights on the actual geometry were obtained by using molecular mechanics (MM) calculations, with the MM3* force field, as implemented in the MacroModel program (Maestro Suite) . In addition, it was also demonstrated that genistein itself, also a plant component, can act as an Αβ oligomer ligand. These results prove that this plant is a source of bioactive compounds with a potential anti-amyloid aggregation effect, useful in the therapeutics of diabetes and/or Alzheimer's disease (AD) and Αβ1-42 oligomers seem to act as an in vitro model of type 2 diabetes for this type of compounds, supporting the results obtained for the extract and for 8-p-D-glucosylgenistein in the biological assays with STZ-induced diabetic rats.
The ethyl acetate and the butanol plant extracts proved to be more potent than acarbose, a standard drug that inhibits a- glucosidase. In addition, both extracts and the diethyl ether extract inhibited significantly glucose-6-phosphatase, an enzyme acting on gluconeogenesis , a target of therapy for type 2 diabetes, and on glycogenolysis .
Synthesis of compounds type A
Preparation of compound A (X=Y=Z=OH, R=H, sugar residue: glucosyl, 10) was accomplished according to Scheme 1.
Scheme 1. a) 1. DMF, NaH, 30 min., 0 °C; 2. BnBr, 24 h, r.t., 87 %; b) AcOH, H2S04 2N, 24 h, 90-95 °C, 81 %; c) Ac20, Py, 1 h, r.t, 96 % ; d) 1. DMF, K2C03, 30 min, 0 °C; 2. BnBr, 1 h, r.t.; e) DCE, Sc(OTf)3, Drierite, 30 min., -30 °C then 5 h, r.t., 49%; f) 1. 1,4-dioxane, aq. NaOH 50% (w/v) , 18 h, reflux, 2. Ac20, Py, DMAP, 1 h, r.t., 60 %; g) 1. TTN (III), (MeO)3CH, MeOH, 24 h, 40 °C; 2. THF, MeOH, aq. NaOH 50 % (w/v), 4 h, r.t., 63 %; h) MeOH, EtOAc, Pd/C, 6 h, r.t., 96 %.
The following modifications to the reported methods were used:
A) Benzylation of acetophloroglucinol
Scheme 2. Synthesis of the starting material 2 , 4-dibenzyloxy- 6-hydroxyacetophenone (6) was successfully accomplished in one single step by benzylation of acetophloroglucinol with BnBr (2 eq.) and K2C03 in DMF for 1 h isolated in 69 % yield, while the method used by Sato et al.9 and described by Kumazawa et al synthesized this compound in four steps,
reproduced in overall yield of 36%, although reported as 71%. This methodology is more advantageous than the reported in the literature avoiding several protection/deprotection and purification steps.
Example lj Synthesis of 2, 4-dibenzyloxy-6- hydroxyacetophenone (6)
To a solution of 5 (59.6 mmol) in DMF was added K2C03 (2.2. equiv.) . After stirring for 10 min at 0°C, BnBr (2.2. equiv.) was added and the mixture stirred for 1 h at room temperature .
HC1 2M was added and the mixture was poured into water and extracted with EtOAc. Organic layers were combined, washed with brine, dried over MgSC>4 and concentrated. Compound 6 was purified by CC (10:1 hexane/EtOAc) in 69 % yield. Rf = 0.73 (4:1 P. Ether/EtOAc) ; pf. 103.5-104.0 °C (Lit. [66] p.f. = 108-109 °C); XH RMN (CDC13) δ 14.17 (s, 1H, OH-8); 7.47-7.40 (m, 20H, CH, Ph) ; 6.22 (d, 1H, J5,7=2.32 Hz, H-7); 6.15 (d, 1H J5,7=2.32 Hz, H-5); 5.09 (s, C¾Ph-4); 5.08 (s, C¾Ph-6) ; 2.61 (s, 3H, H-l); 13C RMN (CDC13) δ 203.2 (C-2); 167.6 (C-6 e C-8); 162.1 (C-4); 135.9 (Cq-4) ; 135.7 (Cq-6); 128.8; 128.7; 128.5; 128.4; 128.1; 127.7 (CH, Ph) ; 106.3 (C-3); 94.8 (C-7); 92.4 (C-5); 71.2 (CH2Ph-6); 70.3 (CH2Ph-4); 33.4 (C-l) .
B) Glucosylation of 2, 4-dibenzyloxy-6-hydroxyacetophenone (6)
Sato and co-workers used glucosyl fluoride as glucosyl donor. When repeating the reported procedure, unidentified byproducts were formed. In alternative, a cleaner reaction was obtained using l-O-acetyl-2 , 3 , 4 , 6-tetra-O-benzyl-D-
glucopyranoside (4) as glycosyl donor and catalytic amount of Sc(OTf)3 as activator. The C-glycosylation of 6 proceeded initially at -30 °C and then at room temperature for 5 h giving product 3 in 49% yield.
Synthesis of 4 in 81% yield was also a clean reaction by treatment of methyl 2 , 3 , 4 , 6-tetra-O-benzyl-a-D-glucos ide with AcOH and H2S04 2N at 90-95 °C for 24 h.
Example 2: Synthesis of 3- ( 2 , 3 , 4 , 6-tetra-0-benzyl- -D- glucopyranosyl ) -4, 6-dibenzyloxy-2-hydroxyacetophenone (7) a) Preparation of the glucosyl donor
a.l) Synthesis of methyl 2 , 3 , 4 , 6-tetra-O-benzyl-a-D- glucopyranoside (2)
To a 1M solution of NaH in DMF at 0 °C (4.4 eq.) was added dropwise a 1.3 M solution in DMF of methyl D-glucopyranoside (5.14 mmol) . The reaction mixture was stirred for 30 minutes at 0 °C and then temperature was allowed to increase to room temperature. BnBr (4.4 eq.) was added dropwise and the stirring continued for more 24 h. MeOH was added (1 mL) and DMF removed. The residue was dissolved in DCM, washed with water and brine. The organic layer was dried over MgSC>4 and concentrated. The resulting syrup was purified on a silica gel column (15:1 P. Ether -EtOAc) to give compound 2 (87 %) as colorless oil: Rf 0.68 (3:1 P. Ether/ETOAc) ; XH RMN (CDC13) δ 7.54-7.31 (m, 20H, CH, Ph) , 5.19, 5.17 (part A of AB system, 1H, J=11.13 Hz, C¾Ph) , 5.04, 5.01 (part A of AB system, 1H, J=10.86 Hz, C¾Ph) , 5.02, 4.99 (part B of AB system, 1H, J=11.26 Hz, C¾Ph) , 4.93, 4.90 (part A of AB system, 1H, J=12.21 Hz, C¾Ph) , 4.83 ( d, 1H, ^,2=3.85 Hz, H-l), 4.82,
4.79 (part B of AB system, 1H, J=12.21 Hz, C¾Ph) , 4.75, 4.72 (part A of AB system, 1H, J=11.89 Hz, C¾Ph) ; 4.68, 4.65 (part B of AB system, 1H, J=10.94 Hz, C¾Ph) , 4.62, 4.59 (part B of AB system, 1H, J=11.81 Hz, C¾Ph) , 4.21 (t, 1H, J3,4=9.25 Hz, H-3), 3.94 (ddd, 1H, J5,6a=1.73 Hz, J5,6b=3.23 Hz, H-5), 3.90-3.78 (m, 3H, H-4, H-6a, H-6b), 3.75 {dd, 1H, J2,3=9.67 Hz, H-2), 3.52 (s, 3H, OMe) ; 13C R N (CDC13) δ 139.9, 138.4, 138.4, 138.1 (Cq, Ph) , 128.7, 128.6, 128.6, 128.3, 128.2, 128.1, 128.1, 127.8, 127.9 (CH, Ph) , 98.4 (C-l), 82.3 (C-3), 80.0(C-2), 77.8 (C-4), 75.9, 75.2, 73.7, 73.8 (4 CH2, Ph) , 70.2 (C-5), 68.6 (C-6), 55.4 (C, OMe).
a.2) Synthesis of l-O-acetyl-2 , 3 , 4 , 6-tetra-O-benzyl-D- glucopyranose (4)
To a solution of 2 (9.0 mmol) in AcOH (79.5 mL) was added a solution of H2S04 2N (39.5 mL) and the reaction mixture was stirred at 90-95 °C for 24 h. Cold water (300 mL) was added and the stirring continuing for 30 minutes. A white powder was recrystalized from hot EtOAc, filtered off and washed with hexane and dried in vacuum affording compound 3 in 81% yield .
Rf = 0.54 (Et.P/EtOAc 3:1), mp . 135.8 - 137.4 °C; XH RMN (CDCI3) δ 7.37-7.15 (m, 60H, CH, Ph) ; 5.25 ( d, 2H, Jla,2=3.52 Hz, H-la) ; 4.99-4.50 (m, 25H, Η-Ιβ, C¾Ph) ; 4.43 (t, 1H,
Hz, Η-2β); 3.75-3.41 (m, 10H, H-2a, Η-3β, Η-4β, H- 4a, Η-5β, H-6 a and b) ; 4.07 (ddd, 2H,
Hz, H-3a) ; 13C RMN (CDC13) δ 138.7; 138.2; 137.9; 137.8 (Cq, Ph a); 137.8; 137.9; 138.5; 138.4 (Cq, Ph β) ; 128.5; 128.4;
128.4; 128.2; 128.1; 128.0; 127.9; 127.9; 127.8; 127.7; 127.7 (CH2Ph a and β) ; 97.5 (C-Ιβ) ; 91.3 (C-la) ; 84.6 (C-3 ) ; 83.1 (0-2β); 81.8 (C-3a) ; 79.97 (C-2a) ; 77.8 (C-4a) ; 74.7 (0-4β) ; 75.8; 75.1; 75.0; 73.5; 73.3 (CH2Ph a); 75.7; 75.1, 74.8; 74.5 (CH2Ph β); 70.25 (C-5a, β); 68.9 (C-ββ) ; 68.6 (C-6a)
Compound 3 was dissolved in pyridine (10 mL/g) and acetic anhydride (5 mL) at room temperature. The mixture stirred for 30 min and pyridine was removed and compound 4 (α/β=3:1) were purified by CC (6:1 P. Ether/EtOAc) in 96% yield. Rf =0.79 (3:1 P. Ether/EtOAc) ; XH RMN (CDC13) δ 7.42-7.20 (m, 80H, CH, Ph) ; 6.46 (d, 3H,
Hz, H-3a) ; 3.65-3.84 (m, 14H, H-2a, Η-2β, Η-3β, H-4 a and β, Η-5β, H-6 a and b) ; 3.93-3.97 (m, 1H, H-5a) ; 2.12 (s, 3H, OCH3 β); 2.10 (s, 9H, OCH3 a); 13C RMN (CDC13) δ 169.5 (CO, Aca) ; 169.4 (CO, Αοβ); 138.7; 138.4; 138.1; 138.0; 137.9; 137.8; 137.6 (Cq, Ph a and β) ; 128.6; 128.5; 128.4; 128.0; 127.9; 127.9; 127.9; 127.8; 127.7; 127.7; (CH2Ph a and β) ; 94.1 (C-Ιβ); 90.0 (C-la); 81.7 (C-3a) ; 81.1 (0-3β) ; 78.9 (C- 2a); 77.0 (C-4a e β) ; 75.8; 75.5; 75.1; 73.3 (CH2Ph a); 75.8; 75.4; 73.6; 73.6 (CH2Ph β) ; 75.1 (0-2β); 72.9 (C-5a) ; 68.1 (C-6 a and β) ; 21.2 (OCH3, Aca); 21.2 (OCH3, Αοβ) b) Glucosylation reaction
Compounds 4 (2.20 mmol) and 6 (2.0 equiv.) were dissolved in DCE (10 mL) in the presence of drierite (ca. 100 mg) . The solution was stirred at -30 °C and Sc(OTf)3 (0.25 equiv.) was added. The stirring continued for 30 min at -30 °C and then at room temperature for 5 h. The reaction was quenched with
water and filtered through celite, extracted with DCM and concentrated. Compound 7 was purified by CC (10:1 P. Ether/EtOAc) and obtained in 49 % yield. Rf =0.33 (4:1 Et.P./EtOAc) ; XH RMN (CDC13) δ 14.54; 14.36 (s cada, 1H, OH- 2)*; 7.53-7.00 (m, 30H, CH, Ph) ; 6.06; 6.01 (s cada, 1H, H- 7)*; 5.17-4.31 (m, 13H, C¾Ph, H-l'); 3.91-3.58 (m, 6H, H-2', H-3', H-4', H-5', H-6a' e H-6b' ) ; 2.63; 2.60 (s cada, 3H, H- 1)*; 13CR N (CDCI3) 5 203.6; 203.4 (C-2)*; 165.1. 165.0 (C-4)*; 164.2; 163.5 (C-6)*; 162.5; 162.3 (C-8)*; 139.1; 138.9; 138.6; 138.5; 138.4;138.3; 136.2; 135.6; 135.5; (Cq. Ph) *; 128.9; 128.9; 128.7; 128.5; 128.4; 128.4; 128.1; 128.0; 127.9; 127.8; 127.7; 127.6; 127.5; 127.3; 127.1; 126.9 ( CH . Ph)*; 106.8; 106.7 (C-5)*; 105.9; 105.5 (C-3)*; 89.3; 89.1 (C-7)*; 87.9 (C-3'); 79.8; 79.4 (C-5')*; 78.6; 78.3 (C-4')*; 75.7; 75.5; 75.2; 75.1; 72.8; 72.4; 70.7; 70.1 (CH2Ph); 74.3 (C-2'); 71.1; 70.9 (C-l')*; 69.7 (C-6'); 33.8; 33.7 (C-l)*; * two peaks were observed, corresponding to rotamers as described by Sato et al .
C) Aldol condensation
Reaction of the C-glucosyl derivative 7 and 4- benzyloxybenzaldehyde with aq. NaOH 50% (w/v) followed by acetylation led to compound 9 in 60% overall yield. These conditions proved to be reproducible while those reported by Sato consisting on treatment with 28% NaOMe-MeOH (solution), followed by stirring at room temperature for 20 h did not result in the expected reaction yield.
Example 3: Synthesis of 1- [2-acetoxy-3- (2, 3, 4, 6-tetra-O- benzyl- -D-glucopyranosyl) -4, 6-dibenzylox ] phenyl-3- (4- benzyloxyphenyl ) prop-2-en-l-one (8)
To a solution of 7 (2.80 mmol) and p-benzyloxybenzaldehyde (1.5 equiv.) in 1,4-dioxane (27.9 mL) was added an aq. solution NaOH 50 % (27.9 mL) . The reaction mixture was stirred in reflux for 24 h. After this time HC1 2M was added and the mixture was extracted with DCM, washed with brine, dried over MgS04 and concentrated.
The residue was dissolved in pyridine (10 mL/g residue) and acetic anhydride (2.0 equiv. /OH) . The mixture was stirred for 30 min and then pyridine was removed. Compound 8 was purified by CC (5:1 P. Ether/EtOAc) in 60 % overall yield. Rf = 0,50 (3:1 P. Ether . /EtOAc) ; XH RMN (CDC13) δ 7.49-7.21 (m, 38H, CH, Ph, H-3, H-3', H-5'); 6.96 (d, 1H J2, , 3, =8 , 62Hz , H-6'); 6.91 (d, 1H J2, 3=16, 15 Hz, H-2); 6.43 (s, 1H, H-5"); 5.14 (s, 2H, C¾Ph-7); 5.04-4.14 (m, C¾Ph, H-l'", H-2'"); 3.91-3.58 (m, H-3'", H-4'", H-5'"; H-6a" ' , H-6b" ' ) ; 2.08 (s, 3H, OC¾, Ac); 13C RMN (CDC13) δ 191.9 (C-l); 169.1 (CO. Ac); 160.6 (C- 6"); 159.5 (C-l'. C-4'); 157.4 (C-4"); 149.0 (C-2"); 144.9 (C-3); 138.8; 138.6; 138.5; 137.9; 136.5; 136.4 (Cq, Ph) ; 136.0 (Cq, Ph-7); 128.7; 128.7;128.6; 128.5; 128.4; 128.3; 128.2; 128.1; 128.00; 127.9; 127.8; 127.7; 127.6; 127.5; 127.4; 127.3; 127.2; 127.1; 126.9. 126.1 (CH, Ph) ; 126.2 (C- 3', C-5'); 125.9 (C-2); 118.3 (C-l"); 114.9 (C-2', C-6' ) ; 112.8 (C-3"); 96.3 (C-5"); 86.9 (C-3'"); 80.9 (C-2'"); 79.1 (C-5'"); 77.9 (C-4'"); 75.9; 74.9; 73.7; 74.2; 73.2; 71.4; 70.8 (CH2Ph); 73.9 (C-l'"); 69.8 (CH2Ph-7); 68.8 (C- 6" ' ) ; 20.9 (OCH3) .
D) Oxidative rearrangement
The oxidative rearrangement of chalcones using TTN (III) in methanol was firstly described by Horie et al. The authors suggested that the OH groups in chalcones need to be protected, preferentially by esters such as an acetyl or benzoyl groups, since the hydrogen bond between carbonyl and OH groups interfere in the interaction of the double bond with tallium. Sato and co-workers reported acidic conditions for the cyclization and synthesized compound 9 in only 33% yield. In this invention the reaction was performed in basic conditions using an aqueous solution of NaOH 50%, leading to the formation of perbenzylated C-glucosylisoflavone in 63 % yield .
Example 4: Synthesis of 8- ( 2 , 3 , 4 , 6-tetra-0-benzyl- -D- glucocopyranosyl ) -4' , 5, 7-tribenzyloxyisoflavone (9)
TTN (2.0 eq.) was added to a solution of 8 (1.67 mmol) in (MeO)3CH (45 mL) and MeOH (45 mL) . The reaction mixture stirred for 24 h at 40 °C and then sodium bissulfite was added to promote the reduction of Tl (III) to Tl (I) . Solid was removed by filtration, water was added and the mixture was extracted with DCM. The combined extracts were dried over MgS04, filtered off and concentrated.
The yellow residue was dissolved in THF (21 mL) and MeOH (21 mL) and then, aq. NaOH 50% (8.6 mL) was added and the reaction stirred for 4 h at room temperature. After reaction
completed HCl 2M was added and the mixture was extracted with DCM, dried over MgSC>4, filtered off and concentrated. The residue was separated by CC (5:1 P. Ether) to give 9 in 63 % overall yield. Rf = 0.45 (Et.P/EtOAc, 3:1); XH RMN (CDC13) δ 7.92 (s, 1H, H-2); 7.54-7.03 (m, 35H, CH, Ph) ; 6.87 (d, 2H, J2',3'; 5', 6'= 7.23 Hz, H-2', H-6'); 6.78 (d, 2H, H-3', H-5'); 6.43 (s, 1H, H-4); 5.25-4.14 (m, 14H, C¾Ph, H-l"); 3.95- 3.60 (m, 6H, H-2", H-3", H-4", H-5", H-6a", H-6b") 13C RMN (CDCI3) δ 181.8 (C-4), 163.9 (C-7), 162.5 (C-5), 155.7 (C-8a) , 152.8 (C-2), 138.5, 138.3, 138.2, 137.8, 136.8, 135.9, 135.8 (Cq, Ph) , 128.7, 128, 6, 128, 5, 128, 4, 128, 3, 128, 2, 128, 1, 128.0, 127.9, 127.8, 127.6, 127.5, 127.3, 127.2, 127.1 (CH, Ph) , 122.8 (C-3), 107.7 (C-4a) , 104.1 (C-8), 96.94 (C-6), 87.8 (C-2"), 79.6 (C-3"), 78.5 (C-4"), 75.6, 75.2, 75.1, 74.2, 73.5, 73.1, 71.0 (CH2Ph), 74.5 (C-5"), 68.78 (C- 6" ) .
E) Debenzylation
Removal of all benzyl groups of 9 was accomplished with MeOH/EtOAc in the presence of a catalytic amount of Pd/C under hydrogen atmosphere for 2 h at room temperature and compound 10 was obtained in 93 % yield. In alternative, Sato9 used 20wt % of Pd(OH)2/C under H2 atmosphere and the reaction took 5 h at room temperature, giving 94% yield, which confirmed that these conditions are time consuming and do not improve reaction yield.
Example 5. Synthesis of 8- -D-glucopyranosylgenistein ( 10 )
Pd/C (25 mg) was added to a solution of 9 (0.094 mmol) in MeOH (3 mL) and EtOAc (1 mL) which stirred for at room temperature for 2 h unde hydrogen atmosphere. Catalyst was filtered off under celite and washed with MeOH. The filtrate was concentrated and purified by CC (6:1 P. Ether/ EtOAc) . Compound 10 was obtained in 96 % yield. Rf = 0.35 (1:1 P. Ether /EtOAc); XH RMN (MeOD) δ 8.12 (s, 1H, H-l); 7.37 ( d, 2H, J2'3'=8.67 Hz, H-2', H-6'); 6.84 ( d, 2H, J2'3'=8.67 Hz, H-3', H- 5'); 6.29 (s, 1H, H-6); 4.95-4.90 (m, 1H, H-l")*; 4.14-4.09 (m, 1H, H-2"); 3.50-3.40 (m, 1H, H-3"); 3.90-3.71 (H-4", H-5", H6a" e H-6b" ) ; 13C RMN (MeOD) δ 182,7 (C-4); 164.8 (C-7); 163.5 (C-5); 158.9 (C-8a, C-4'); 154.8 (C-2); 131.7 (C-2', C-6'); 124.6 (C-3); 124.3 (C-l'); 116.4 (C-3', C-5'); 105.6 (C-4a) ; 104.8 (C-8); 97.7 (C-6); 72.9 (C-l"; C-2"); 80.2 (C-3"); 71.9 (C-4"); 82.7 (C-5"); 63.0 (C-6"); *H-1 signal is overlapped with the reference signal of MeOD.
Biological activity
Activity of 8-^-O-glucopyranosylgenistein (10) on reducing excessive hyperglycae ia
We evaluated the ability of the δ-β-D-glucosilisoflavone compound obtained through synthesis to counter the hyperglicaemic state seen on an animal model of diabetes .
Animals
Tests were conducted using male Wistar rats, with weight around 250 g. Animals were maintained under stable conditions
of temperature (25°C), light-dark periods (12h) , and feeding (maintenance rat chow) . Both food and water were available ad lib. Food was removed 24h before testing, to ensure that the animals were on the fasting state. Access to water was maintained during this period.
Induction of diabetes
A state of hyperglycaemia adequate to the diagnosis of diabetes was induced experimentally through chemical intervention. A sole intraperitoneal (i.p.) injection of streptozotocin (STZ), previously dissolved in saline, was administered at the dose of 40 mg/kg. Hyperglicaemia was checked two days after STZ administration by quantifying glucose on a blood sample collected by tail puncture. The animals on the control group received instead an injection of the same volume of saline, with normoglycaemia checked also after two days.
Experimental animal groups
Animals were randomly divided into three groups . Group I (Control) was given one saline injection, and two days after started a 7-days treatment with saline + 5% ethanol. This group represents normoglycaemic control. Group II (STZ) was first treated with streptozotocin (40 mg/kg, i.p.) and then for 7 days with saline + 5% ethanol. This group represents the diabetic condition. Group III (STZ+ 8G) was first given STZ (40 mg/kg, i.p.) and then a 7-days treatment with
synthesized 8-C-glucosilisoflavone (4 mg/kg/day in saline + 5% ethanol, i .p . ) .
Glucose tolerance curve and associated insulin parameters
Animals were anesthetised with sodium pentobarbital (65 mg/kg) after a 24h fasting period. Immediately after, they were placed on a homoeothermic apparatus. Body temperature was maintained at 37 °C to avoid metabolic changes induced by hypoglycaemia . An exterior loop was surgically placed between the femoral vein and artery, and a catheter was placed on the stomach. After surgery completion, recovery before testing was allowed for a minimum period of 30 minutes. Anaesthesia was maintained throughout the experiment with a constant sodium pentobarbital perfusion on the femoral vein.
Glucose tolerance testing was done first by monitoring blood glycaemia at the fasting state for 20 minutes, after which 2 ml of a glucose solution (2 mg glucose/kg) was administered through the gastric catheter, directly into the stomach. Blood glycaemia was thus measured at regular intervals, by a bench glucose analyzer, both on baseline fasting (from -20 to 0 minutes) and on the post-load period (from 0 to 180 minutes) .
Blood samples were also collected for insulin and c-peptide quantification, both at baseline and post-load time points (- 20, -10, 0, 5, 15, 30, 45, 60, 90, 120, 180 minutes) . These samples were quickly centrifuged and serum was stored at - 80°C for RIA analysis.
Data analysis
Data is shown as mean ± standard error. Mean relates to n observations, in which n represents the number of animals tested (between 5 and 8, depending on the group) . Mean values between groups were compared using one-way analysis of variance (ANOVA) , followed by a Tukey post-test. Differences were considered statistically significant when p<0.05.
Effect of 8-Beta-D-glucopyranosylisoflavone treatment on diabetic animals
STZ administration induced both higher fasting glucose (from
78.8 ± 2.1 on controls, n=5, to 131.8 ± 16.8 mg/dl on STZ, n=5, at minute 0; p<0.01) and greater glucose excursions (reaching a maximum of 166.4 ± 3.7 on control and of 323.8 ±
45.9 mg/dl on STZ; p<0.01) . Post-load endpoint glycaemia, considered here at 180 minutes after gastric glucose loading, was likewise raised (from 112.0 ± 4.3 on control to 245.4 ± 42.8 mg/dl on STZ; p<0.01) . Total glucose excursion was thus elevated (from an area under the glycaemic curve (AUC) of 23659 ± 990 on controls to 49539 ± 7309 on STZ; p<0.01).
These glycaemic parameters were all returned to normal control values on those diabetic rats subjected to the 7-days i.p. administration of 8-C-glucosilisoflavone (4 mg/kg, daily) . In this group, n=8, fasting glycaemia obtained was
84.4 ± 3.7 (p<0.01 to STZ), maximum post-load glycaemia was 196.5 ± 16.2 (p<0.01), and endpoint post-load glycaemia was
132.8 ± 13.3 (p<0.01) . Total glucose excursion was thus returned to normal (to an AUC of 29865 ± 2484; p<0.01 to the STZ group) .
In relation to (by chemical destruction of pancreatic cells), STZ administration lead to a decrease on glucose-induced insulin secretion, as estimated through c-peptide insulin parameters, as expected quantification (from an AUC of 287124 ± 37907 on controls to 172261 ± 18480 on STZ; p<0.05) and likewise a decrease on circulating insulin (from an AUC of
323.9 ± 50.6 on controls to 137.3 ± 54.4, p<0.01) . The animals subjected to the short-term treatment with 8-C- glucosilisoflavone showed a partial amelioration of these parameters (insulin secretion: 226892 ± 3972, circulating insulin: 219.0 ± 15.6), however not yet with statistical difference .
These results show that a short-term (7 days) treatment with 8-C-glucosilisoflavone (4 mg/kg/day, i.p.) is able to return fasting glycaemia and post-load glucose excursions to normal, while producing yet a modest amelioration of insulin secretion. This leads to the conclusion that 8-C- glucosilisoflavone is able to also act by increasing insulin sensitivity .
Acute Toxicity of 8- -D-glucopyranosylgenistein
The potential toxicity of δ-β-D-glucopyranosylisoflavone was evaluated. The in vitro acute toxicity of this compound in
eukaryotic cells was assessed using the MTT cell viability assay. The results quantified as IC50 values are summarized in Table 1. Isolated compound showed a low toxic effect, with IC50 values almost 10 times higher than the commercial drug chloramphenicol .
Table 1. IC50 values of in vitro acute toxicity of the isolated compound of Genista tenera in eucaryotic cells using the MTT cell viability assay.
IC5o (mg/mli) StDev
DMSO 0,199 0, 037
H202 0, 002 0, 002
Chloramphenicol 0,143 0, 010
Isolated
1,250 0, 003
compound
MTT method
Acute cytotoxicity measurements were performed by the MTT method. The 3- ( 4 , 5-dimethylthiazol-2-yl ) -2 , 5- diphenyltetrazolium bromide (MTT) assay was used to quantify metabolically viable cells in all samples. Adherent cells (mouse HII4E hepatoma cells) were seeded onto 96-well plates, allowed to attach for 24 h and exposed to the test compound for the following 24 h. Positive control (hydrogen peroxide), negative control (DMSO) and chloramphenicol were also included. At 48 h of culture, MTT was added to the cells at a final concentration of 0.5 mg/mL, followed by an incubation period of 3 h to allow the formazan crystals to form. After incubation, medium was removed, cells were washed twice to remove traces of medium and un-metabolized MTT, and DMSO (100
L) was added to each well. Solubilisation of formazan crystals was performed by agitation in a 96-well plate shaker for 20 min at room temperature. Absorbance of each well was quantified at 550 nm, using 620 nm as reference wavelength on a scanning multiwell spectrophotometer (automated microplate reader) .
Extract preparation and biological activities
Plant material
Aerial parts of Genista tenera were collected in the Island of Madeira, dried in the absence of direct sunlight, and pulverized to form a plant powder.
Extract preparation
Plant powder was extracted with ethanol 96% (Panreac, VWR) , in a Soxhlet extractor. The ethanol extract was concentrated to dryness at low temperature (40 °C) under reduced pressure, in a rotary evaporator Buchi R-200.
The ethanol extract was suspended in hot water (80 °C) and flavonoids extracted sequentially with diethyl ether, ethyl acetate and n-butanol. The tree different extracts were concentrated to dryness in a rotary evaporator Buchi R-200.
This invention concerns to the ethyl acetate extract of flavonoids .
Antihyperglycaemic activity
The antihyperglycemic activity of the Genista tenera flavonoid extract was evaluated in a mammal model.
Administration of the extract
The extract was dissolved in saline + 5% de ethanol (v/v) and administered (60 mg/Kg/day.), for 7 days
Animals
Adult male Wistar rats, (200-300 g) were used throughout the studies .
Animals were maintained under stable conditions of temperature (25°C) , light-dark periods (12h) , and feeding (maintenance rat chow) . Both food and water were available ad libitum. Food was removed 24h before testing, to ensure that the animals were on the fasting state. Access to drinking water was maintained during this period.
Animals were divided into three groups, each containing 4 to 6 rats :
Group I (Normoglycaemic control)
Group II (Diabetic control)
Group III (Diabetic+ Extract)
Experimental induction of diabetes
To induce hyperglycaemia, animals were injected intraperitoneally (i.p.) with a single dose (40 mg/Kg) of streptozotocin (STZ) dissolved in saline.
Extract effect in diabetic animals
Animals were divided into three groups:
Group I: Normoglycaemic control (saline+ 5% ethanol, i.p.),
Group II: Diabetic control (STZ, 40 mg/Kg, saline+ 5 ethanol, i.p.) ,
Group III: Diabetic+ Extract (60 mg/Kg/day, i.p.)
Extract was given daily, for seven days .
Oral Glucose Tolerance Test (OGTT)
At day 7, it was performed the OGTT assay. Animals received orally (10 mL/Kg) a glucose solution (20%, w/v) and plasma glucose levels were determined at 0 (baseline), 5, 15, 30, 60, and 120 min, with a Glucometer (Accutrend Check, Bohering-Manheim) .
Extract effect in normoglycaemic animals
Animals were divided into two groups: control group was injected (i.p.) with the solvent of the extract (saline + 5% ethanol) , while a second group was treated with the extract (60 mg/Kg, i.p.), 5 min before the OGTT.
Statistical analysis
Data are shown as mean ± standard error. Mean relates to n observations, in which n represents the number of animals tested (4 - 6) . Mean values between groups were compared
using the Student's t-test. Differences were considered statistically significant when P<0.05.
Fasting glucose levels were significant reduced (c.a. 50%) in diabetic rats treated for seven days with the extract (60 mg/Kg/day, i.p.).
At this dose, after glucose overload (OGTT) no hypoglycaemic activity was observed in normoglycaemic animals treated with the extract.
The extract displays encouraging efficacy in normalizing glucose levels of STZ diabetic rats.
Evaluation of the antidiabetic mechanism shown by the ethyl acetate and n-butanol plant extracts
The mechanism of the antidiabetic activity of the extracts was evaluated in terms of their inhibitory activity on the enzymes a-glucosidase and glucose-6-phosphatase, which are involved in the metabolism of glucose. The ethyl acetate, n- butanol and diethyl ether were tested, according to the following procedures:
Inhibition of a-glucosidase
Sample preparation
The extract samples were firstly dissolved in DMSO, at the concentration of 20 mg/mL. 10 L of this solution were added to 90 L of maleate buffer (0,1 M; pH=6, 9) , being the final tested concentration 400 mg/L.
Inhibitory assay
Enzyme solutions were prepared using rat intestinal acetone powder (Sigma, St. Louis, Mo., USA) as the source of a- glucosidase. 50 mg of rat intestinal acetone powder were homogenized with 10 mL of 0,1 M maleate buffer at pH 6.9 and centrifuged at 6000 xg for 20 min at 4°C. The supernatant obtained before the experiment was used as the enzyme solution for the alpha-glucosidase reaction. The experimental procedure was carried out by the methology of Mai and coworkers, although with slight modifications. 50 L of the enzyme solution was pre-incubated with 50 L of the plant extract solution and 100 L of 0,1 M maleate buffer (PH 6,9) at 37 °C for 10 min. The enzyme reaction was then started by adding 50 L of maltose substrate solution (1% w/v in maleate buffer (pH 6.9)) . The enzymatic reaction was allowed to proceed at 37 °C for 30 min and then stopped by heating at 100°C for 5 min.
The generated glucose was quantified with a commercial assay kit ( Sigma-Aldrich) at 540 nm. A control was run with 150 L of maleate buffer 0,1 M (pH=6.9) instead of the extract sample. For blank determination, the enzyme solution was replaced with 0,1 M maleate buffer and the same procedure was carried out as above. Acarbose was tested as reference compound, in a concentration of 400 mg/L. Each extract sample or controls were measured five times. The rate of a- glucosidase inhibition was calculated as a percentage of the control by the formula below:
%inhibition= (Ac-As) /Ac x 100,
Where As is the difference in absorbance decrease at 540 nm between a blank and a sample; Ac is the absorbance of the
control. The final concentration of the extractor reference compound for a-glucosidase inhibitory activity was determined under the essay conditions and was expressed as mg/L.
Statistical analysis
Mean values between groups were compared using one-way analysis of variance (ANOVA) , followed by a Tukey post-test. Differences were considered statistically significant when p<0.05. Statistical analysis was performed using the Statistica program, version 6.0.
The ethyl acetate and n-butanol extracts revealed a significant a-glucosidase inhibition (enzymatic activity reduced to 2,36 % and 0,97%, respectively) being these two extracts much more effective than the standard drug acarbose, which reduced the enzymatic activity to 17,39 %.
Inhibition of glucose-6-phosphatase
Sample preparation
The extracts samples were firstly dissolved in DMSO, at the concentration of 20 mg/mL. 40 L of this solution were added to 60 L of HEPES 10 mM (0,1 M; pH=6,5), being the final tested concentration 400 mg/L.
Inhibitory assay
Enzymatic solution was prepared with rabbit liver microsomes as a source of glucose- 6-fosfatase as described previously.
The microsomal protein (16.74 mg) was resuspended in 0.837 mL HEPES (5 mM ,pH 6.5) containing 0.25 mM sucrose, and 1 mM MgC12, and frozen at-80 °C until use.
Enzymatic assays were performed by the method described by Burchell et al. with some modifications.
Briefly, the G-6-Pase assay was carried out in a final volume of 100 i with 5 mM glucose- 6-phosphate (G-6-P) , 2 mM EDTA, 16 mM HEPES pH 6.5 (solution A) and the enzyme.
The reaction was carried out at 37 °C for 60 min without shaking, and stopped by the addition of 1 mL of sulphuric acid (0.33 M) , 0.28% ammonium molybdate, 1.11% SDS and 1.11% ascorbic acid (solution B) .
The reaction was incubated at 47 °C for 20 min and the absorption recorded in a Shimadzu UV-1700, at 820 nm. In order to study the effect of each extract, it was added to the G-6-Pase assay at a final concentration of 400 mg/mL.
The final concentration of DMSO in control and experimental assays was 2.0%. Phlorizin, dissolved in DMSO (10%) was used at the same concentration of the extracts, as a positive control .
Statistical analysis
Mean values between groups were compared using one-way analysis of variance (ANOVA) , followed by a Tukey post-test. Differences were considered statistically significant when p<0.05. Statistical analysis was performed using the Statistica program, version 6.0.
The ethyl acetate, n-butanol and diethyl ether extracts from Genista tenera revealed some inhibition of the glucose-6- phosphatase enzyme at the catalytic unit and, eventually, at the Tl transporter. These results are very interesting, once they suggest that the extracts can play a role on the decreasing of the hepatic glucose production, which may be important to the control of type 2 diabetes.
Binding properties of 8-^-D-glucopyranosylgenistein, genistein 7-0-glucoside, genistein and the ethyl acetate extract with beta-amyloid oligomers
The presence of compounds able to bind Αβ1-42 oligomers in ethyl acetate extract of G. tenera was investigated by using NMR experiments, as described below:
Sample preparation
A batch of Αβ1-42 was selected that contained pre- amyloidogenic seeds highly toxic to N2a cells. The selection was made through sample characterization by NMR spectroscopy, as previously described Immediately before use, lyophilized Αβ1-42 was dissolved in 10 mM NaOD in D20 at a concentration of 160μΜ, then diluted 1:1 with 10 mM phosphate buffer saline, pH 7.4 containing 100 mM NaCl (PBS) and ethyl acetate extract of G. tenera or one of the tested compounds. In particular, the final concentrations/quantities of Αβ1-42, genistein-8-C- glucoside, genistein-7-O-glucoside, genistein and the ethyl acetate extract of G. tenera in the samples were 80 uM, 2 mM, 1 mM, 1 mM and 3 mg respectively. The pH of each sample was
verified with a Microelectrode (Mettler Toledo) for 5 mm NMR tubes and adjusted with NaOD and/or DC1. All pH values were corrected for isotope effect.
For the quantitative NMR experiment, 1,5 mg of ethyl acetate extract of G. tenera was dissolved in 550 L of D20 and DSS was added to the final concentration of 0.4 mM.
Molecular Mechanics (MM) calculations
Molecular mechanics were conducted with MacroModel 9.8.207 as implemented in version 9.1.207 of the Maestro suite, using the MM3* force field. A systematic variation of the torsional degrees of freedom of the molecules permitted generating different starting structures that were further minimized to provide the corresponding local minima. Only the same two minima were always found for each molecule (0- and C- glucosides) . The continuum GB/SA solvent model was employed and the general PRCG ( Polak-Ribiere Conjugate Gradient) method for energy minimization was used. An extended cut-off was applied.
NMR spectroscopy binding studies
NMR experiments were recorded on a Varian 400-MHz Mercury instrument. The basic VARIAN sequences were employed for 2D- TOCSY, 2D-NOESY, 13C-HSQC, DOSY and STD experiments. For STD, a train of Gaussian-shaped pulses each of 50 ms was employed to saturate selectively the protein envelope; the total saturation time of the protein envelope was adjusted by the number of shaped pulses and was varied between 3 s and 0.3 s. A 1H spectrum was acquired with a recycle delay of 60 s to
achieve the complete relaxation of all the resonances at each scan. The quantification was performed by comparing the DSS methyl resonance integral with the δ-β-D- glucopiranosylgenistein aromatic resonance integrals.
• Binding properties of the ethyl acetate extract
Upon addition of the Αβ1-42 oligomers to the NMR tube containing the extract solution, a first clue of the existence of interaction was deduced by the existence of broadening for several signals in the 1H NMR spectrum of the extract. Fittingly, the STD spectrum contained several NMR signals, belonging to molecules present into the extract and indicated, in a non-ambiguous manner, the existence of their interactions with the Αβ1-42 oligomers (figure 8) . Additional evidences of the existence of interaction was deduced from analysis of trNOESY experiments acquired on the same ligand : peptide mixture. The results from this experience reflect an increase of the effective rotational motion correlation time of the molecule in the presence of the Αβ oligomers, strongly supporting the existence of a binding process of the small molecules present in the extract to the peptide oligomeric state (figure 9) .
• Binding properties of 8-^-D-glucopyranosylgenistein
The shape of the observed signals in both the STD and trNOESY spectra suggested the presence of 8-β-ϋ- glucopyranosylgenistein, reported as one of the most abundant molecule found in the ethyl acetate extract of G. tenera. To further confirm the interaction of the 8-β-ϋ- glucopyranosylgenistein with the Αβ oligomers, the same NMR
experimental protocol was repeated on a mixture containing Αβ1-42 peptide and the pure compound at both 25°C and 37°C. The results unequivocally demonstrate that δ-β-D- glucopiranosylgenistein is bound to Αβ oligomers. The STD intensities (Figure 10) clearly indicated that the aromatic aglycone is mostly involved in the binding. Nevertheless, several sugar resonances also appeared, suggesting their participation in the interaction process.
An indication of the orientation of the glucoside with respect to the oligomer was deduced from inspection of the trNOESY cross peaks (figure 11), which suggests that, in the bound state, the glucoside adopts a preferential conformation in which its a-face points towards H2 at the fused bicyclic moiety of the aglycone.
Insights on the actual geometry were obtained by using molecular mechanics (MM) calculations, with the MM3 force field, as implemented in the MacroModel program (Maestro Suite) . Two possible conformations around the glycosidic linkage were identified, which only differed in 2,6 kJ/mol. The global minimum (defined by an anti-geometry for the HlGic _ ClGic _C8-C7 torsion angle) is shown in violet in Figure 14, while the alternative local minimum (with a syn orientation) is displayed in yellow.
• Binding properties of genistein 7-O-glucoside
The analysis of a 1H-NMR 2D DOSY spectrum acquired on the G. tenera extract at 25°C allowed to calculate a diffusion coefficient of 2.65 ± 0.035 10~10 m2/s for this compound vs. a diffusion coefficient of 3.5 ± 0.02 10"10 m2/s found for the
genistein-8-C-glucoside, indicating that this new ligand behaves in solution as a larger molecular entity. The STD spectrum obtained allows assessing that also genistein-7-O- glucoside was bound to Αβ1-42 peptide, and supported that this is indeed the second component of G. tenera extract interacting with the oligomeric target (figure 12) . The existence of broad signals in the extract, as well as its insolubility when pure in PBS, is probably due to the existence of intermolecular stacking among several molecules. Indeed, the conformational search performed with the MM3* force field indicated that this compound may assume two extended iso-energy conformations (Figure 15), which would easily permit the existence of intermolecular aromatic- aromatic or carbohydrate-aromatic stacking. The formation of a supramolecule would explain the slow diffusion coefficient found for this molecule in the extract solution.
• Binding properties of genistein
Additional STD (Figure 13) and trNOESY experiments were performed for the genistein aglycone in the presence of the Αβ1-42 peptide oligomers. They also demonstrated that genistein itself is an efficient Αβ oligomer ligand. The results described above prove that this plant is a source of bioactive compounds with a potential anti-amyloid aggregation effect, useful in the therapeutics of diabetes and/or Alzheimer's disease (AD) and Αβ1-42 oligomers seem to act as an in vitro model of type 2 diabetes for this type of compounds, supporting the results obtained for the extract
and for 8-p-D-glucosylgenistein in the biological assays with STZ-induced diabetic rats.
Claims
1. Flavonoid extract of Genista tenera characterized by the fact that the extract is obtained from the aerial parts of the plant and the extraction is performed with ethyl acetate .
2. Flavonoid extract of claim 1 wherein the extract is for use as a medicament and/or a nutraceutic or functional food ingredient.
3. Flavonoid extract according to claim 2, wherein the extract is used for treating diabetes.
4. Plant extract according to claim 3, wherein the extract is administered in an amount of 60 milligrams or less per kilogram body weight per day, for seven days, to a mammal model.
5. Use of the extract according to claim 1 for the preparation of a medicament for the treatment of diabetes type 1 or 2, characterized in that the extract is administered intraperitoneally in a dose of 60 mg/Kg or less of body weight.
6. An antidiabetic composition comprising plant extracts from the genus Genista.
7. An antidiabetic composition comprising an ethanol extract of plants from the genus Genista.
8. An antidiabetic composition comprising an ethanolic extract of Genista tenera.
9. An antidiabetic composition comprising the ethyl acetate flavonoid extract from the ethanol extract of Genista tenera .
10. Pharmaceutical composition comprising the plant extracts of claims 1 to 9, without hypoglycaemic effects in normoglycaemic animals.
11. Pharmaceutical composition comprising the plant extract of claims 1 to 9 that normalizes blood glucose levels on the oral glucose tolerance test (OGTT) .
12. A pharmaceutical preparation in dosage unit form adapted for administration to obtain a therapeutic effect, comprising, per dosage unit, a therapeutically effective amount of the plant extract of claims 1 to 9.
13. Medical use of the plant extract of claims 1 to 5, for treatment of diabetes, wherein a dose of 60 mg/kg or less of body weight is administered.
14. A method for treatment of diabetes comprising the step of administering a quantity of flavonoid extract from Genista tenera, to result in a reduction of hyperglycaemia .
15. Pharmaceutical composition comprising ethyl acetate and n-butanol extracts from Genista tenera that inhibit the enzyme a-glucosidase, normalizing glucose levels.
16. Pharmaceutical composition comprising diethyl ether, ethyl acetate and n-butanol extracts from Genista tenera that inhibits the enzyme glucose-6- phosfatase, normalizing glucose levels.
17. Ethyl acetate extract from G. tenera according to claim 1 acts as antiamyloidogenic for Alzheimer's disease .
18. Ethyl acetate extract from G. tenera according to claim 1 acts a new ligand of β amyloid (A β) oligomers.
19. Ethyl acetate extract from G. tenera according to claim 1 acts as a new ligand of Αβ1-42 oligomers.
20. δ-β-d-Glucosylgenistein for the control of glycaemia on a diabetic animal models, both on the fasting and post-load periods.
21. 8- -D-Glucosylgenistein according to claim 20 for the control of glycaemia on a diabetic animal model, both on the fasting and post-load periods.
22. δ-β-D-Glucosylgenistein (4 mg/kg/day or less, 7 days) according to claims 20 and 21 for the return of basal fasting glycaemia.
23. 8- -D-Glucosylgenistein (4 mg/kg/day or less, 7 days) according to claims 20, 21 and 22 for the return of post-load glucose excursions to normal control values on rats made diabetic by prior destruction of pancreatic cells with streptozotocin (40 mg/kg) .
24. 8- -D-Glucosylgenistein according to claim 20, to interfere beneficially, by itself or by any product of its metabolization, on various parameters of glucose and insulin metabolic pathways.
25. 8- -D-Glucosylgenistein according to claims 20 to 24, by itself or by any product of its metabolization, to increase glucose-induced insulin secretion, by direct or indirect interaction with pancreatic cells.
26. δ-β-D-Glucosylgenistein according to claims 20 to 24, by itself or by any product of its metabolization, is able to increase insulin sensitivity, by direct or indirect interaction with peripheral cells, which are mainly, but not exclusively, skeletal muscle myocytes.
27. 8- -D-Glucosylgenistein according to claims 20 to
24, as a low toxic agent in eukaryotic cells, ten times less toxic than chloramphenicol, when evaluated by the MTT cell viability assay.
28. 8- -D-Glucosylgenistein according to claim 20 acts as antiamyloidogenic for Alzheimer's disease.
29. 8- -D-Glucosylgenistein according to claims 20 and 22 acts a new ligand of β amyloid (A β) oligomers.
30. δ-β-D-Glucosylgenistein according to claims 20 to 29 that acts as a new ligand of Αβ1-42 oligomers.
31. Pharmaceutical composition comprising 8-β-Ό- glucosylgenistein in combination with several flavonoids identified in the ethyl acetate extract of G. tenera.
32. Genistein 7-0^-D-glucoside, present in ethyl acetate extract of G. tenera according to claim 1 acting as antiamyloidogenic for Alzheimer's disease.
33. Genistein 7^-D-0-glucoside present in ethyl acetate extract of G. tenera according to claims 1 acting a new ligand of β amyloid (A β) oligomers.
34. Genistein 7^-D-0-glucoside present in ethyl acetate extract of G. tenera according to claim 1 acting as a new ligand of Αβ1-42 oligomers.
Genistein present in ethyl acetate extract of tenera according to claim 1 acting as antiamyloidoge for Alzheimer's disease.
36. Genistein present in ethyl acetate extract of G. tenera according to claim 1 acting as new ligand of β amyloid (A β) oligomers.
Genistein present in ethyl acetate extract of G. tenera according to claim 1 acting as a new ligand of Αβ1-42 oligomers.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/384,145 US9775856B2 (en) | 2012-03-09 | 2013-03-11 | C-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of Genista tenera ethyl acetate extracts containing some of those agents |
EP13744800.7A EP2822653B1 (en) | 2012-03-09 | 2013-03-11 | New c-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of genista tenera ethyl acetate extracts containing some of those agents |
US15/681,459 US20170348340A1 (en) | 2012-03-09 | 2017-08-21 | New c-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of genista tenera ethyl acetate extracts containing some of those agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT106202 | 2012-03-09 | ||
PT10620212 | 2012-03-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/384,145 A-371-Of-International US9775856B2 (en) | 2012-03-09 | 2013-03-11 | C-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of Genista tenera ethyl acetate extracts containing some of those agents |
US15/681,459 Continuation-In-Part US20170348340A1 (en) | 2012-03-09 | 2017-08-21 | New c-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of genista tenera ethyl acetate extracts containing some of those agents |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013132470A2 true WO2013132470A2 (en) | 2013-09-12 |
WO2013132470A3 WO2013132470A3 (en) | 2014-02-20 |
Family
ID=48914366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2013/051916 WO2013132470A2 (en) | 2012-03-09 | 2013-03-11 | New c-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of genista tenera ethyl acetate extracts containing some of those agents |
Country Status (3)
Country | Link |
---|---|
US (1) | US9775856B2 (en) |
EP (1) | EP2822653B1 (en) |
WO (1) | WO2013132470A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107880080A (en) * | 2017-12-20 | 2018-04-06 | 江汉大学 | A kind of synthetic method of 2,3,4,6 tetrabenzyl D glucopyranoses |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000003684A2 (en) * | 1998-07-16 | 2000-01-27 | Aaron Tabor | Soy formulations and their use for promoting health |
-
2013
- 2013-03-11 US US14/384,145 patent/US9775856B2/en not_active Expired - Fee Related
- 2013-03-11 EP EP13744800.7A patent/EP2822653B1/en active Active
- 2013-03-11 WO PCT/IB2013/051916 patent/WO2013132470A2/en active Application Filing
Non-Patent Citations (1)
Title |
---|
None |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107880080A (en) * | 2017-12-20 | 2018-04-06 | 江汉大学 | A kind of synthetic method of 2,3,4,6 tetrabenzyl D glucopyranoses |
Also Published As
Publication number | Publication date |
---|---|
WO2013132470A3 (en) | 2014-02-20 |
EP2822653B1 (en) | 2024-06-19 |
EP2822653A2 (en) | 2015-01-14 |
US20150031639A1 (en) | 2015-01-29 |
US9775856B2 (en) | 2017-10-03 |
EP2822653C0 (en) | 2024-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4709203B2 (en) | Argin oligosaccharide and its derivatives, and their preparation and use | |
Chen et al. | Identification of ellagitannins in the unripe fruit of Rubus Chingii Hu and evaluation of its potential antidiabetic activity | |
AU2017385332B2 (en) | Composition of mannuronic dicarboxylic acid | |
SA98190501B1 (en) | APPETITE SUPPRESSANT Pharmaceutical compositions with appetite suppressant activity | |
Thao et al. | Isolation, semi-synthesis, docking-based prediction, and bioassay-based activity of Dolichandrone spathacea iridoids: new catalpol derivatives as glucosidase inhibitors | |
KR102410619B1 (en) | A composition comprising the isolated compound 1 from an extract of alder tree for treating and preventing skeleton muscle-related disorder | |
Ohara et al. | Synthesis and bioactivity of β-(1→ 4)-linked oligomannoses and partially acetylated derivatives | |
TWI619721B (en) | Isoacteoside derivative and forming method and use thereof | |
CN108350014A (en) | Aminoglycoside derivative and its application in treating hereditary conditions | |
US6376682B1 (en) | Compound with α-glucosidase inhibiting action and method for producing the same | |
Si et al. | Isolation and characterization of phellodendronoside A, a new isoquinoline alkaloid glycoside with anti-inflammatory activity from Phellodendron chinense Schneid | |
JP2015212255A (en) | Pharmaceutical and food compositions for preventing or treating diabetes or obesity | |
Li et al. | Flavonoid glycosides from seeds of Hippophae rhamnoides subsp. Sinensis with α-glucosidase inhibition activity | |
KR100828192B1 (en) | Pharmaceutical composition comprising dammarane compounds showing kidney protecting activity | |
CN103288913B (en) | A kind of noval chemical compound, its pharmaceutical composition, Its Preparation Method And Use | |
US9775856B2 (en) | C-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of Genista tenera ethyl acetate extracts containing some of those agents | |
US20170348340A1 (en) | New c-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of genista tenera ethyl acetate extracts containing some of those agents | |
CN108752404B (en) | A kind of berberine salt derivative and its preparation method and application that triazole is sugar-modified | |
US7531519B2 (en) | Polygalatenosides and use thereof as an antidepressant agent | |
CN113603570B (en) | Leonurine borneol derivative, preparation method and application thereof | |
WO2011106691A2 (en) | Curcumin derivatives | |
WO2013172436A1 (en) | Novel glycosylated compound of crocin, method for producing same, and use for same | |
Song et al. | Synthesis of nature product kinsenoside analogues with anti-inflammatory activity | |
CN103340881B (en) | The application in neuroprotective of a kind of oligosaccharide compound | |
KR101481141B1 (en) | Pharmaceutical Composition for Preventing or Treating Diabetes Containing Novel Compound Lobarstin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 14384145 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013744800 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13744800 Country of ref document: EP Kind code of ref document: A2 |